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1.1 Metabolic adaptions as consequence of genetic alterations in cancer 
Cancer is the second most cause of death in the industry nations. Recent estimations 
turned out that for example up to almost 50 % of every individual citizen in Germany will 
develop cancer during its lifetime 1. Moreover a meta-analysis estimated the costs for 
cancer treatment in the European Union to be 126 billion Euro per annum 2. Therefore 
developing an effective treatment of cancer is a cross-national concern. 
The cause for cancer can be found in a multistep process of accumulation of genetic 
alterations in non-cancerous cells. These genetic alterations are induced by a set of 
factors like chemical agents, ionizing radiation, virus infection or it originates from 
incorrect genome replication 3. Most of these genetic changes affect genes, encoding for 
proteins which are part of signal transduction cascades or are involved in cell-cycle 
control. According to their way of action 
they are termed oncogenes or tumor-
suppressor genes. Oncogenes are 
activated by mutations leading to a gain 
of function, whereas alterations of 
tumor-suppressor genes lead to a loss 
of function 4. 
Although the amounts of genetic 
damages causing cancer seem 
numerous, the principles underpining 
the characteristics of a malignant cell 
can be described by six general 
features 5. Hanahan and Weinberg state 
that every cancer cell is self-sufficient in growth signaling, insensitive to antigrowth-
signals, evasive of apoptosis-signals, limitless in replicative potential, sustaining in 
angiogenesis and prone to invade other tissues and form metastasis (Figure 1). 
Moreover, within the present decade, Hanahan and Weinberg extended their concept. 
They described four new abilities of malignant cells, two enabling characteristics and 
two emerging hallmarks 6. The enabling characteristics are the genome instability and 
Figure 1: The six hallmarks of cancer. Picture adapted from 




the tumor-promoting inflammation. The two emerging hallmarks are avoiding of 
immune destruction and deregulation of cellular energetics. Especially the latter has 
come into focus over the recent years since more and more functions of oncogenes and 
tumor-supressor are described in terms of their involvement in the metabolism of 
cancerous cells 7. 
Controlling cell proliferation (by tightly regulated signaling cascades and cell cycle 
control) are not the only bottlenecks tumors have to circumvent to maintain their 
antisocial behavior. They also have to surpass limitations in their energy- and nutrient 
supply by adjusting their metabolism. It was described that many enzymes of glucose 
metabolism are affected in tumors in terms of a deregulated expression rate or 
activity 8 9. Moreover, glucose transport, lipogenesis, respiration and nucleotide 
synthesis are also subject to alterations to serve a tumor’s metabolic demands 10. In this 
context an astonishing ability of cancerous cells was described 80 years ago by Otto 
Warburg. He discovered that tumors, although sufficient oxygen-concentrations are 
available, seem to rely mainly on glycolysis- rather than on respiration- to maintain their 
energy supply 11 12 13. This kind of metabolic 
behavior was called “aerobic glycolysis”. Why 
tumors do behave like this is still questionable. 
The more efficient production of ATP by 
respiration (~18 fold) 14 seems suprisingly not to 
be the favored way to generate energy by a lot of 
cancer entities. Within the last decades this 
aspect has been considered to be an alternative 
target for new antitumor-drugs 15. The favoured 
explanation for the use of “aerobic glycolysis” is 
that glycolysis is not primarily used for energy 
supply, but to produce molecules needed for cell 
division 16. Dividing cells have a high consumption 
of fatty acid-, amino acid- and nucleotide 
precursors. Moreover, the reducing equivalents 
in form of nicotineamid adenine dinucleotide 
Figure 2: The conversion of glucose must be 
adjusted. It either serves for energy generation 





phosphate (NADPH) are essential for certain anabolic reactions, forming these 
precursors. Therefore the cell has to adjust the fate of every glucose molecule in terms 
of either being used for energy supply in form of adenosine triphosphate (ATP) via 
glycolysis or as source for NADPH via the pentose phosphate pathway (PPP) (Figure 2). 
Malignant cells seem to adjust this described balance of glucose processing especially by 
inhibiting respiration and thereby increasing the availabilty of glucose for glycolysis and 
PPP especially 16. Over the past years, more and more oncogenes as well as tumor-
supressor genes have been identified, affecting this balance by increasing the oxygen 
indipendent glucose metabolism. A set of proteins involved in this process are 
phosphinositid-3 kinase/protein kinase B (PI3K/AKT), AMP-activated protein kinase/liver 
kinase B1 (AMPK/LKB1), p53 and MYC 7 (Figure 3). 
 
 
Figure 3: Metabolic adjustment by known oncogenes and tumor-suppressor genes. The scheme represents the 
known connection of oncogenes (green boxes) and tumor-suppressor genes (red boxes) to glycolysis, pentose 
phosphate pathway, oxidative phosphorylation and glutamine metabolism in proliferating cells. Adapted from Van der 






PI3K is part of a signaling pathway being quite often affected in human cancers 17. This 
pathway becomes permanently active by mutations in tumor-suppressor genes like the 
phosphatase tensin homolog protein (PTEN). One of the downstream targets of PI3K is 
AKT. Activation of AKT leads to several metabolic changes. It enhances glucose uptake 
by increasing the expression of glucose transporters (GLUT1) and by increasing the 
activity of hexokinase and phosphofructokinase the two enzymes catalyzing irreversible 
steps of glycolysis 18. 
AMPK is a crucial checkpoint for sensing low ATP concentrations. It inhibits glycolysis 
and cell proliferation and shifts towards a respiratory phenotype. Tumors must surpass 
this restriction to increase glucose-availability for glycolysis and PPP. This is caused by 
loss of the activity of the upstream tumor-suppressor gene LKB1, whose activity would 
otherwise lead to phosporolytic activation of AMPK 19. 
Besides many other involvements in cancer development, p53 is also responsible for 
inhibiting glycolysis by an upregulation of the TP53-induced glycolysis and apoptosis 
regulator (TIGAR) 20. TIGAR decreases the levels of the glycolytic enzyme fructose-2, 6-
bisphosphatase leading to downregulation of glycolysis. Moreover p53 induces 
expression of PTEN, a negative regulator of the PI3K pathway mentioned above. Thus, 
inactivation of p53-function leads to a switch towards a glycolytic phenotype in 
cancer 21. 
The oncogene MYC has, within its activity as transcription factor, a major role in the 
glutamine metabolism of proliferative cells. Glutamine is a critical supplemental factor of 
mammalian cells 22. Besides this function MYC was also described to increase the 
expression of pyruvate kinase isoenzyme 2 (PKM2). Pyruvate kinase plays a pivotal role 
in glycolysis by transferring a phosphate group from phosphoenolpyruvate to adenosine 
diphosphate (ADP) leading to the production of ATP. PKM2 is a less active isoform and 
leads to a bottleneck within glycolysis, which increases the availability of glucose for the 
upstream localized PPP. 
All these effects of known oncogenes and tumor-suppressor genes shift tumor cells 
towards an oxygen independent way of metabolism and are the events that lead to the 
deregulation of cellular energetics - one of the above mentioned hallmarks of cancer. It 




of ATP but more likely to increase the amount of glucose available for NADPH- and 
nucleotide-synthesis within the PPP. 
 
1.2 Pentose phosphate pathway 
The pentose phosphate pathway (PPP) (also termed hexose monophosphate shunt or 
phosphogluconate pathway) is responsible for the generation of NADPH, D-ribose 5-
phosphate (R5P) and D-erythrose 4-phosphate (E4P). NADPH is required for anabolic 
reactions and to sustain a cell’s redox state by donating reduction equivalents for 
glutathione production (glutathione is the most common used molecule for balancing a 
cell’s redox-state) 14. R5P serves as precursor for nucleotide synthesis whereas E4P is the 
starting point for aromatic amino acid synthesis in plants and some procaryotes 14. The 
PPP can be seperated into an oxidative and a non-oxidative part (Figure 4). The oxidative 
part is initiated by the stepwise oxidation of D-glucose 6-phosphate (G6P). This 
irreversible step withdraws G6P from glycolysis and the fate of the glucose molecule is 
determined. In the next reaction 6-phosphogluconolactone is oxidatively decarboxylated 
which results in D-ribulose 5-phosphate formation. During this oxidation one mole D-
glucose 6-phosphate leads to the production of 2 mole NADPH. 
In the subsequent non-oxidative part of the PPP D-ribulose 5-phosphate is converted 
into either D-ribose 5-phosphate (R5P), by the activity of an isomerase, or D-xylulose 5-
phosphate (X5P), by an epimerase. These two sugar phosphates now serve as substrates 
for the two enzymes transketolase (TKT) and transaldolase (TA), which are responsible 
for C2- (TKT), or C3- (TA) sugarphosphate fragment transfer. Starting from the two C5 
sugar phosphates the following products are formed: D-glyceraldehyde 3-phosphate 
(G3P), E4P, D-fructose 6-phosphate (F6P) and D-seduheptulose 7-phosphate (S7P). As 
mentioned above the C5 sugar phosphate R5P is used for nucleotide synthesis, whereas 
E4P serves as precursor for aromatic amino acid synthesis in plants and procaryotes. 
G3P and F6P are incorporated into glycolysis vice versa, whereas S7P is an intermediate 





Figure 4: The pentose phosphate pathway. The oxidation of D-glucose 6-phosphate generates 2 mole of NADPH in 
the oxidative part of the PPP. The following non-oxidative reactions give rise to D-ribose 5-phosphate for nucleotide 
synthesis and D-erythrose 4-phosphate for aromatic amino acid synthesis. D-Fructose 6-phosphate and D-





All cells can adjust the rate of glucose being metabolized either within glycolysis or the 
oxidative- or non-oxidative part of the PPP and recruit these metabolic pathways to 
serve their demands in terms of ATP-, NADPH-, aromatic amino acid- or nucleotide-
synthesis 16. In malignant cells this regulation seems to become decoupled in order to 
drive the generation of the above mentioned PPP products to a higher degree. The 
precursors are needed for the enhanced rate of cell division which reflects one of the 
above mentioned hallmarks of cancer. The two enzymes TA and TKT are indispensable 
for the non-oxidative part of the PPP and especially TKT and its isoformes were 
described to play a pivotal role in tumorigenesis. 
 
1.3 Transketolase 
1.3.1 Transketolase, general features and its contribution to human 
diseases 
Transketolases (EC 2.2.1.1) are ubiquitously distributed enzymes and part of the PPP. 
They require thiamin diphosphate (ThDP), the biologically active form of vitamin B1, and 
bivalent cations for their catalytic activity 23 24 25. TKTs are involved in two metabolic 
pathways, namely the previously described PPP and the calvin-benson-bassham cycle of 
photosynthetic plants, where they are responsible for the regeneration of the CO2 
acceptor ribulose 1,5-bishosphate 14. Besides its well known metabolic function, TKT has 
been associated with a couple of diseases like diabetes, Alzheimer’s disease, the 
neurological disorder Wernicke-Korsakoff syndrome and cancer 26 27 28 29 30. In case of 
cancer the impact of an altered TKT activity can be directly explained by its function 
within the PPP. It is assumed that up to 85 % of a cell’s ribose, subsequently used for 
nucleotide synthesis, is produced by the PPP 28. Ribose is directly needed to fuel the cell 
division capacity of malignant cells, since it is the source of nucleotides and therefore for 
DNA replication. This circumstance makes TKT a promising target to inhibit uncontrolled 
cell division of tumor cells. In fact it was reported that inhibition of transketolase activity 







1.3.2 Structure of human transketolase 
The structure of yeast TKT was first solved in 1992 34. In the following years structures of 
TKTs from all domains of life were determined. It has been shown that, although on the 
primary structure level the homogeneity of TKTs was not that striking, the quartery 
structure of all investigated TKTs was strongly conserved 35. The structure of human TKT 
is shown below (Figure 5). Two kidney-formed monomers of transketolase form the 
active dimer of the enzyme. A monomer consists of an N-terminal pyrophosphate-
domain, serving as an anchor for the pyrophosphate of the ThDP cofactor. In the center 
of the enzyme the pyrimidine-domain is located, responsible for binding the 
aminopyrimidine ring of the cofactor. The C-terminal domain was proposed to act as a 
nucleotide binding motif. However, biophysical characterizations do not underpin this 
assumption 25. The active centers of TKT are located at the subunit interface and amino 
acid residues of both monomer units contribute to its formation. 
 
 
Figure 5: Structure of human transketolase. (A) Representation of the biologically active dimer of human 
transketolase. The monomers are colored in green and red, respectively. The cofactor ThDP and the bivalent calcium-
cation (cyan) are depicted in ball representation. (B) Domain-structure of the human transketolase monomer. Shown 
are the PP-domain in red, the PYR-domain in green and the C-terminal domain in yellow. The two linker regions 
















1.3.3 Cofactor activation and reaction mechanism of transketoases 
TKT catalysis requires ThDP and bivalent cations as cofactors. ThDP belongs to the yet 
best characterized cofactors 36 37 38. Its unique structure and chemical properties allow 
enzymes to perform a set of diverse reactions 39. Among those reactions the formation 




Although the structure of ThDP is known since the 30’s of the last century 40 it took until 
1957 when Breslow identified the C2 carbon atom of the thiazolium ring as the critical 
factor for covalent catalysis 41 42 (Figure 6). In the Breslow-mechanism the C2 of ThDP 
becomes activated by abstraction of its proton, leading to an active ylid which is 
necessary for ThDP-reactivity. In solution this Umpolung called reaction occurs in a 
negligible amount of ThDP molecules due to the low acidity of the C2 proton (pKa ~17-
19) 43 44. In ThDP dependent enzymes the cofactor becomes orientated in such a way 
that the N4’ of the aminopyrimidine ring and the C2 of the thiazolium ring are located in 
close vicinity (V-conformation) 45. This fact as well as the charge delocalization in the 
thiazolium part of the cofactor increases the proton abstraction at the C2 by the factor 
of 105 46 47. 
Equilibria of tautomeric and ionized states of the aminopyrimidine ring of the cofactor 
have been describes as characteristic feature of enzyme-bound ThDP mediated 
catalysis 37 48. In almost all ThDP-enzymes the first step of ThDP-activation starts with 
protonation of the 4’-aminopyrimidene (AP) form of the cofactor by a conserved 
glutamate residue (Figure 7). This gives rise to the so called 4’-aminopyrimidinium form 
(APH+) of the cofactor. After deprotonation of the APH+ form at the N4’ of the 




aminopyrimidinium ring the 1’,4’-iminopyrimidine form (IP) is generated. These steps 
facilitate proton abstraction at the C2 of the thiazolium ring, which gives rise to the 




Figure 7: Tautomeric and ionization equilibria of ThDP prior to substrate addition. Adapted from Nemeria et al. 
(2007) 
 
By using circular dichroism spectroscopy, different absorption spectra have been 
assinged to the tautomeric states of the cofactor. The AP form shows a negative 
absorption in the range of ~320-330 nm whereas the IP form gives rise to a positive 
signal between 300-310 nm. The APH+ signal has so far been described as 
spectroscopically silent 49. 
In transketolases the activation of the ThDP occurs as described above leading to the 
activated ylid. After this activation a set of reversible reactions is initiated, beginning 
with the nucleophilic attack of the C2 of the thiazolium at the carbonyl function of the 
substrate (donor ketose), leading to the covalent ThDP adduct (Figure 8). Elimination of 
the first product (aldose phosphate) occurs after protonation of the 3’OH group of the 
intermediate, followed by a heterolytic bond cleavage of the C2α-C3α bond. This gives 




intermediate is now able to react with the second substrate in a nucleophilic manner 
(acceptor aldose) leading to the second product of this reaction cycle 50. 
 
 
Figure 8: Reaction cycle of TKTs. The activated ThDP cofactor attacks the carbonyl function of a donor ketose in a 
nucleophilic manner which gives rise to the donor ketose ThDP-adduct. After release of the first product (aldose) the 
DhEThDP-intermediate is formed. This intermediate now attacks in a similar way an acceptor aldose which leads to 
the second product (ketose). 
 
Besides this well understood raction cycle of TKT it was recently shown that TKT can 
serve to elucidate the general assumption of enzymes to act as transition state 
stabilizers in more detail. High resolution crystal structures of human TKT revealed a 
distortion of the covalent bond between the substrate and the cofactor besides an 
elongated scissile C2α-C3α bond mentioned above within the substrate 51. The unique 
overall structure of TKT seems to keep this transition state intermediate at a higher level 






1.4 The TKT isoforms Transketolase-like protein 1 and 2 
1.4.1 Structural similiarities of TKT, TKTL1 and 2 
TKTs have a central role in the primary glucose metabolism and seem also to be a critical 
determinant for driving a tumor’s metabolism in terms of precursor generation for 
anabolic reactions. Moreover in the human genome two isoenzymes were discovered, 
namely transketolase-like protein 1 and 2 (TKTL1, TKTL2). Especially for TKTL1 a critical 
role in tumorigenesis has been proposed 52 53. 
The sequence identity on the genome level between TKTL1 and TKT is 69 % whereas the 
identity of TKTL2 to TKT is 71 % 54. For several cancer entities such as breast cancer 55, 
glioblastoma 56 and cervix carcinoma 57 an increased expression of TKTL1 on the mRNA 
and protein level has been described. Besides it was demonstrated that an elevated 
expression rate of TKTL1 directly correlates with a lowered over time survival of patients 
suffering from cancer. Coy and coworkers hypothesized TKTL1 to be a crucial 
determinant in the aggressiveness of all in this regard investigated cancers. Contrary, no 
informations of the biological function of TKTL2 have been published so far. 
The comparison of the amino acid sequence of TKT and TKTL1 results in an exon deletion 
observed in TKTL1, leading to the loss of 38 amino acids within the protein (Figure 9). 
Several residues that are inherently conserved amongst all so far investigated TKTs are 
located in the deleted part 35. One of the deleted residues corresponds to histidine 103 
in yeast, whose exchange against alanine was reported to increase a one substrate 
reaction of TKT with X5P as substrate in the yeast homolog 58. Coy et al. reported a 
comparable one substrate reaction with TKTL1 and X5P as substrate, leading to the 
formation of G3P and a C2-fragment of unknown identity 53. This reaction is believed to 
follow a similar mechanism as it was described for phosphoketolases of 
heterofermentative lactid acid bacteria and Bifidobacteria 59. However the difference of 
TKT and TKTL1 is more dramatic than the exchange of this single amino acid. In total 
nine inherently conserved amino acids are exchanged or are totally missing in TKTL1 
(Figure 9). Besides six invariant residues in the deleted 38 amino acid sequence (Gly 76, 
His 77, Tyr 83, Gly 90, His 110 and Pro 111), Ser 74, Gly 152 and Pro 426 are also 
exchanged. The exchange of glycine 152 against serine can be considered as most 




motif which is crucial for all ThDP-enzymes 60. These changes challenge the assumption, 
that TKTL1 can bind ThDP as cofactor and fulfill ThDP-dependent chemistry. 
However, the authors assume that TKTL1 connects the PPP and the degradation of 
glucose in a way allowing tumors to drive lipid synthesis without the need of the citric 
acid cycle. The C2 fragment of unknown identity was assumed to be acetyl Coenzyme A, 
which can be further used to fuel lipid synthesis. Based on this activity the authors 
declare TKTL1 to be a crucial factor for the establishment of an aerobic glycolytic 
phenotype in cancer. Several studies have been published connecting an increased 





Figure 9: Sequence alignment of hTKT (p29401) against TKTL1 (p51854). Numbering corresponds to the sequence of 
human TKT. Secondary structure elements are extracted from pdb-structure 3MOS (hTKT). Identical residues are 
highlighted by a red background, similar ones by red characters. The deletion of 38 amino acids in TKTL1 is indicated in 
blue. Asterisks mark residues which are invariant amongst all TKT sequences. For missing residues in TKTL1 see text. 
Alignment and data presentation was performed with ClustalW2 and ESPript 2.3 respectively. An alignment of human 








1.4.2 TKTL1 and tumorigenesis 
Several physical and biochemical characteristics of different cancers and cancer derived 
cell lines have been associated with an increased TKTL1. In the following section a short 
synopsis is given, summarizing the most striking results on which metabolic changes 
have been correlated to an overexpression of TKTL1 in malignant cells. 
 
 siRNA mediated suppression of TKTL1 in a colon carcinoma cell line (HCT-116) 
leads to a slower cell growth, a lowered glucose consumption and lactate 
production as well as an increased sensitivity to reactive oxygen species 61 
 comparable results were found for a cervical derived cell line (HeLa) and a gastric 
adenocarcinoma cell line (AGS cells), in which the total TKT activity was also 
affected 57 62 
 TKTL1 expression was described to correlate with a higher rate of metastasis 
formation in histopathological thyroid and ovarian carcinoma samples 63 64 
 in surgically removed breast cancer specimens an activation/upregulation of AKT 
and GLUT1 was correlated to an increased expression of TKTL1 65 
 another group detected a correlation between TKTL1 and lactate 
dehydrogenase 5 expression in non-small lung cancer tissue samples, which 
contributes to the establishment of a fermentative phenotype of cancer 66 
 a study of cervical carcinoma in terms of TKTL1 and phosphorylated AKT 
expression showed an increase of expression for both proteins, connected to a 
higher histopathological grade of the cervical tissue 67 
 in a murine model TKTL1 was found to play a role in adjusting the downstream 
balance of the PPP, resulting in the production of anti inflammatory molecules by 
NADPH 68 
 in 2012 Wanka et al. reported that TKTL1 seems to be a downstream target of 
the TP53 induced glycolysis and apoptosis regulator (TIGAR) in glioblastoma 
derived cell lines; inhibition of TKTL1 by siRNA reversed the protective effects of 




Taken together these results indicate TKTL1 to be important for driving a tumors 
metabolism towards a more active glycolysis and PPP and thereby leading to 
independence from oxygen supply. Therefore it seems reasonable to assume that TKTL1 
plays a crucial role for the production of R5P and NADPH by serving the tumors needs of 
these biomolecules for anabolic reactions and defense against reactive oxygen species. 
How TKTL1 overexpression contributes to the observed effects is still under investigation 
but recent results indicate an involvement of TKTL1 in the stabilization of the hypoxia 
inducible factor 1α (Hif1α). 
 
1.4.3 TKTL1 putatively contributes to tumorigenesis by Hif1α stabilization 
Sun and coworkers showed that expression of TKTL1 on the mRNA and protein level is 
driven by promoter hypomethylation in head and neck squamos cell carcinoma (HNSCC) 
cell lines O11, O28 and 22A 70. In a previous study the same group reported TKTL1 
overexpression in HNSCC cell lines FaDu and UM22B to have proliferative effects, 
whereas a knockdown of TKTL1 reversed this outcome 71. In the recent study Sun et al. 
could show that TKTL1 overexpression leads to an increase of F6P and G3P production 
(both products of the PPP and glycolysis). Production of pyruvate, lactate and ATP was 
also raised, as well as glucose consumption. Some of these metabolic effects have been 
described earlier for a colon carcinoma cell line, as mentioned above (HCT-116) 61. The 
authors furthermore investigated, whether the hypoxia inducible transcription factor 1α 
(Hif1α) is affected by the elevated levels of the mentioned metabolites, as it was already 
described in an earlier study 72. 
Hif1 is an oxygen-sensitive transcription factor, adjusting a cells adaptation to changing 
oxygen availability 73. It is a heterodimer consisting of a Hif1α and a Hif1β monomer. 
Hif1α is localized in the cytosol, whereas Hif1β is located in the nucleus. Under normoxic 
conditions the constitutively expressed Hif1α becomes hydroxylated at distinct proline 
residues by the activity of prolyl-hxdroxylases. The marked Hif1α is now prone to 
degradation by the proteasom. If the cell faces oxygen restriction Hif1α is accumulated 
in the cytosol by inhibition of the prolyl-hydroxylase activity (PHD) and is being 
translocated into the nucleus. Here it forms, together with Hif1β, the active transcription 




these genes are responsible for recruiting new blood vessels, to stimulate oxygen supply 
of the tumor (angiogenesis). On the other hand they also stimulate cell proliferation to 
escape the hypoxic environment. The last adaption of Hif1 leads to an increase of 
expression of glycolytic enzymes and glucose transporters which switches the 
metabolism towards oxygen independent 
glycolysis and PPP 74. Indeed, Sun et al. 
could show that Hif1α is stabilized even in 
the presence of ample oxygen 
concentrations. This leads to an activation 
of several Hif-downstream targets like 
hexokinase 2, aldolase and 
phosphoglycerate kinase, crucial enzymes 
of glycolysis. This stabilization of Hif1α by 
TKTL1 even in the presence of oxygen 
seems to be a reasonable explanation how 
TKTL1 promotes aerobic glycolysis in 
cancer and increases the rate of glycolysis 
and PPP (Figure 10). 
 
1.4.4 The role of TKTL1 is contradictory 
The concept of TKTL1 promoted tumorigenesis leading to higher rates of metastasis 
formation and lowered over time survival of patients by the described mechanisms is 
not accepted by all scientists. There are well-founded doubts about the concept of a 
glycolytic phenotype established by TKTL1 75. The main argument of these scientists is 
the unspecificity of the antibody used for detection of TKTL1 in surgically removed 
specimens and western blots. This antibody was generated by Coy and coworkers in 
2005 (JFC12T10) and is used for most studies dealing with TKTL1 expression analysis 
since then 53. Mayer et al. performed a set of experiments aiming to detect TKTL1 on the 
mRNA (by qRT-PCR) as well as on the protein level (by western blotting and 
histopathological immunostaining). For western blot analysis different cell lysate 
fractions were generated from HeLa and MCF-7 cells. By blotting the lysate and 
Figure 10: The proposed mechanism of TKTL1-driven 




subsequent exposure to the JFC12T10 the blots gave rise to a set of bands between 44 
to 95 kDa that could not be explained. Besides the western blot analysis Mayer et al. 
performed qRT-PCR of six different cell lines (HeLa, MCF-7, A549, HT1080, M21 and TF-
1). In none of the end-point RT-PCR analysis a significant overexpression of TKTL1 could 
be detected in comparison to TKT. 
The nonspecific behavior of the antibody was also reported by another group 76. 
Hartmannsberger et al. detected several protein bands of varying size from 40-78 kDa in 
western blot applications of different cell lines (PCI-1/13, FaDu, HeLa, THP-1, SkBr3, HCT-
8) by use of the JFC12T10 antibody. Significant TKTL1 expression could only be detected 
in a HEK293 cell which was transfected with a TKTL1 construct and in THP-1 cells 76. 
siRNA mediated knock down led to a decrease in one of the detected bands (65 kDa), 
but the other bands were unaffected. These bands might represent alternative splice 
variants of TKTL1, missing the target sequence of the siRNA. However it is more likely 
that the bands between 40 and 78 kDa correspond to unspecific stained proteins. 
Derived from these inconsistencies immunohistochemical stainings and deduced 
expression strengths of TKTL1 in the corresponding tumor tissue samples have to be 
interpreted with caution if the mentioned antibody is used. 
Despite the questionable specificity of the TKTL1 antibody (JFC12T10) and rather 
reproducible qRT-PCR analysis TKTL1 is believed to have an effect on tumorigenesis as 
outlined previously by stabilizing Hif1α. But whether TKTL1 leads to the observed effects 
caused by an enzymatic activity of TKTL1 itself or by increasing the activity of other 
metabolic enzymes is still not clear. As mentioned above TKTL1 is proposed to perform a 
reaction similiar to the X5P cleavage reaction of phosphoketolases 53. 
 
1.5 Phosphoketolase 
1.5.1 Phosphoketolase of Bifidobactaria 
Phosphoketolases are the central metabolic enzyme of heterofermentative lactic acid 
bacteria and Bifidobacteria 59. Phosphoketolases of heterofermentative lactic acid 
bacteria use X5P solely as substrate. Therefore they are termed xylulose 5-phosphate 




glycolysis intermediate) and acetyl phosphate, a compound further used for ATP 
production. 
 
In Bifidobacteria phosphoketolases are able to use X5P as well as F6P as substrates and 
are therefore termed xylulose 5-phosphate/fructose 6-phosphate phosphoketolases 
(XFPK) (EC 4.1.2.22). In the so called bifid shunt of Bifidobacteria XFPK is the main 
metabolic enzyme (Figure 11). Here XFPK cleaves F6P into E4P and acetyl phosphate. 
Acetyl phosphate is used for ATP generation. E4P instead is, together with another F6P 
molecule, cycled through the PPP leading to formation of two molecules X5P, which are 
Figure 11: The bifid shunt of 
Bifidobacteria. G6P derived 
F6P is cleaved by XFPK into 
acetyl phosphate and E4P. E4P 
is cycled, together with 
another F6P molecule, through 
the PPP, giving rise to two 
additional X5P molecules 
which are also cleaved by 
XFPK. This final cleavage 
generates another acetyl 
phosphate and G3P. Acetyl 





finally also processed by XFPK. This leads to the generation of two additional acetyl 
phosphate molecule and G3P which fuels glycolysis in an above described manner. 
 
1.5.2 Structure of XFPK from Bifidobacterium breve 
Although already described since the 1950’s 77 as active in several procaryotic and 
eukaryotic specimens, little was known about the enzymatic and structural properties of 
phosphoketolases until recently. In 2010 the structures of XFPK from Bifidobacterium 
longum and B. breve were published, revealing some structural properties of this 
enzyme 78 79 80. Since XFPK and TKT are both ThDP-dependent enzymes acting on the 
same set of substrates (X5P, F6P), XFPK was thought to share some structural similarities 
with TKT. And indeed the solved structure of XFPK revealed a high degree of similarity to 
TKT. As it was observed for TKT, two kidney-shaped monomers contribute to the 
formation of the biologically active dimer of XFPK (Figure 12) 78 80. XFPK consists of three 
domains which can be assigned comparable to TKT. The N-terminal PP-domain is 
responsible for binding of the pyrophosphate-portion of the ThDP-cofactor, whereas the 
PYR-domain interacts with the aminopyrimidine ring of ThDP. The C-terminal has so far 
no described function. 
 
Figure 12: Structure of B. breve XFPK. A) Representation of the biologically active dimer of BbXFPK. The monomers 
are colored in green and red, respectively. The cofactor ThDP as well as the bivalent magnesium-cation (cyan) is 
depicted in ball representation. B) Domain-structure of the BbXFPK monomer. Shown are the PP-domain in red, the 










The active centers of the two monomers are located at the interface and several amino 




Figure 13: The active centers of XFPK from B. breve and human TKT. Most of the residues are conserved except those 
that are responsible for binding of the second substrate (phosphate) in XFPK (Gln 549, Glu 437 and Tyr 501). Gln 428 is 
a human transketolase specific exchange. The corresponding His 553 in XFPK is conserved among all other TKTs. 
 
As shown above (Figure 13) the active centers of human TKT and XFPK from B. breve 
share a high degree of similiarity. The four histidines (His 64/37, His 97/77, His 142/110 
and His 320/258) are conserved. Besides, the replacement of histidine 553 against 
glutamine 428 is a human transketolase specific change. In all TKTs from other 
organisms this histidine is conserved 35. In XFPK these histidine residues are important 
for the single catalytic steps by acting as acid/base catalysts as it will be discussed later. 
Asparagine 549 and tyrosine 501 are part of the phosphate binding site and are 
therefore specific for XFPKs as TKTs do not act on inorganic phosphate as substrate. A 
very interesting exchange can be found in close vicinity to the aminopyrimidinepotion of 
the ThDP cofactor. Threonine 342 is exchanged against glutamate 437 in XFPKs. This 
charged residue might affect the tautomerization/charge equilibria of the cofactor as 
described above and might be an explanation for the different catalytic activity of XFPKs 
























1.5.3 Reaction mechanism of XFPK 
The consistence of TKT and XFPK on the structural level is also reflected in the reaction 
both enzymes catalyze. In case of XFPK a donor ketose (X5P or F6P) is attacked at its 
carbonyl function in a nucleophilic manner, resulting in the ketose-ThDP adduct. After 
aldose cleavage DhEThDP is formed. Histidine 64 and histidine 320 are believed to be 
involved in the first catalyic step by protonating the donor-sugar at the 3’-OH leading to 
the first product (G3P) and intermediate (DhEThDP) 80. At this point the reaction steps 
catalyzed by TKT and XFPK diverge. TKT ligates the C2-fragment to an acceptor aldose, 
leading to the formation of the second sugar-phosphate product. In XFPK, on the 
contrary, water elimination occurs. In this model histidines 97, 142 and 553 are 
supposted to be responsible for protonation of DhEThDP which leads to water 
elimination and formation of the second intermediate (enolAcThDP). After 
tautomerization of the enolAcThDP the ketoAcThDP intermediate is formed which is 
believed to be attacked by inorganic phosphate in a nucleophilic manner, yielding acetyl 
phosphate as a final product (Figure 14). According to Yevenes and Frey, water-






Figure 14: Reaction cycle of XFPK. The activated ThDP cofactor attacks the carbonyl function of a donor ketose in a 
nucleophilic manner, which gives rise to the donor ketose ThDP-adduct. After release of the first product (aldose) the 
DhEThDP-intermediate is formed. Subsequently a water-elimination takes place leading to the enolAcThDP 
intermediate. After tautomerization the ketoAcThDP is assumed to be attacked in a nucleophillic manner by inorganic 
phosphate leading to the product acetyl phosphate. Adapted from Yevenes and Frey (2008). 
 
It is still unclear if acetyl thiamin diphosphate (AcThDP) is indeed an intermediate 
occurring during XFPK mediated catalysis, or if water-elimination and nucleophilic attack 
of phosphate occur in a concerted mechanism. The latter seems more likely since 
phosphate was shown to be a nucleophile too weak to attack AcThDP diphosphate in 
aqueous solution 82. The reaction with water is much more preferred (0.2 s-1) which 
results in formation of acetate 83. In XFPK this reaction must be supressed as it was 
shown for pyruvate oxidase (POX) of Lactobacillus plantarum, another phosphate using 
enzyme, where hydrolysis of the formed AcThDP occurs with 0.03 s-1 84. Moreover 
pyruvate processing in POX leads to the stepwise transfer of two electrons from the 
formed hydroxymethyl thiamine diphosphate intermediate (HeThDP) to a flavin 




which is nucleophilic attacked by phosphate, coupled to the transfer of the second 
electron 85. By this concerted mechanism the low nucleophilicity of the phosphate can 
be overcome, leading to the formation of acetyl phosphate. However in XFPK no such 
mechanism has been described. 
It is also possible that the second substrate, phosphate, plays a more sophisticated role 
in the catalytic model of XFPK. Besides for several enzymes a mechanism is proposed in 
which a phosphate-containing substrate acts as acid/base catalyst, or anchor of a water 
molecule. This was shown for serine proteases, GTPases and type II restriction 
endonucleases 86. Although such results were deduced from structural data and model 
system based approaches, it is imaginable that in case of XFPK phosphate acts as catalyst 
and facilitates tautomerization of the enolAcThDP to the ketoAcThDP. 
 
1.6 Motivation 
Cancer is a disease caused by stepwise genetic alterations in non-cancerogenous cells. 
Most of these alterations affect genes of signaltransduction cascades, 
transcriptionfactors or cell cycle control proteins. Additionally, over the recent years 
more and more evidences have been found that alterations in metabolic enzymes seem 
to play an important role in cancer development too. Such alterations include mutations 
in metabolic enzymes itself, an adjustment of their transcription-rate or an altered 
catalytic activity. Of great interest is the pentosephosphate pathway (PPP) since it is the 
main source of nucleotides and reductive equivalents, making it indispensable for cell 
division and anabolic reactions. In the PPP the two enzymes transketolase (TKT) and 
transaldolase (TA) are in the focus of research. Inhibition of TKT was shown to have 
inhibitory growth-effects on malignant cells. Besides a TKT isoenzyme has been 
discovered which seems to cover the question of an altered PPP-activity in malignant 
cells. This transketolase-like protein 1 (TKTL1) was shown to be overexpressed on the 
mRNA- as well as on the protein-level in several cancer entities. Moreover, its increased 
expression rate seems to correlate with the overall survival of patients suffering from 
cancer. How TKTL1 is influencing this process is still under investigation but the most 




other metabolic pathways like the synthesis of lipids and increases the overall flux 
through the PPP itself. 
 
Since the proposed catalytic function of TKTL1 has not been elucidated in detail it was 
the aim of this thesis to address this question. For that purpose TKTL1 was 
recombinantly expressed and analyzed by spectroscopic methods. Furthermore two 
model systems were established to elucidate the putative functions of TKTL1 in a 
comparative manner. The first alternative system is a deletion variant of native human 
TKT, lacking 38 amino acids that are missing in TKTL1. By spectroscopic methods and an 
enzymatic assay the question was adressed if the missing 38 amino acid residues are 
important for cofactor binding and catalysis. The second model system was the 
phosphoketolase of Bifidobacterium breve whose structure was recently published. By 
comparing structural information as well as spectroscopic analysis of the proposed 
reaction mechanism it served to be compared to a putative TKTL1 mediated reaction. 
 
2. Material and methods 
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2 Material and methods 
All molecular and microbiological methods were performed, if not mentioned otherwise, 
as described in Current Protocols in Molecular Biology 87. For all described molecular 
biological methods heat-sterilized glass envelopes (3 h at 180 °C) as well as sterile plastic 
articles were used. For media, buffers and solutions double-distilled water (ddH2O) was 
used and autoclaved if required (121 °C, 20 min). Heat-labile solutions were sterilized by 
filtering (0.22 µm pore size). 
 
2.1 Materials 
All chemicals were purchased from Sigma-Aldrich (Munich, Germany), Carl Roth GmbH & 
Co. KG (Karlsruhe, Germany) or AppliChem GmbH (Darmstadt, Germany), if not stated 
otherwise. 
 
Acetic acid Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Acetyl coenzyme A, sodium salt Sigma-Aldrich (Munich, Germany) 
Acetyl phosphate Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Acrylamide Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Agar AppliChem GmbH (Darmstadt, Germany) 
Agarose  AppliChem GmbH (Darmstadt, Germany) 
Ammonium chloride Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Antifoam 204 Sigma-Aldrich (Munich, Germany) 
Phenylmethylsulfonylfluoride (PMSF)  AppliChem GmbH (Darmstadt, Germany) 
2-(Bis(2-hydroxyethyl)amino)acetic acid 
(BICINE) 
AppliChem GmbH (Darmstadt, Germany) 
Calcium chloride hexahydrate Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
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Carbenicillin  AppliChem GmbH (Darmstadt, Germany) 
Coenzyme A hydrate Sigma-Aldrich (Munich, Germany) 
Coomassie Brilliant Blue G250  AppliChem GmbH (Darmstadt, Germany) 
Cover plates, 18 mm (siliconized) Jena Bioscience GmbH, (Jena, Germany) 
Cryoloops (0.05 – 0.1 mm) Hampton Research Corp, (CA, USA) 
Crystallization plates, greased Hampton Research Corp, (CA, USA) 
Deuterium oxide 99.9% Sigma-Aldrich (Munich, Germany) 
Dimethylsulfoxide (DMSO) Sigma-Aldrich (Munich, Germany) 
Ethylenediaminotetraaceticacid (EDTA)  AppliChem GmbH (Darmstadt, Germany) 
Ethanol (denatured) Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Ethanol (purest) Nordhäuser Spirituosen GmbH 
(Nordhausen, Germany) 
Formamide Sigma-Aldrich (Munich, Germany) 
D-fructose 6-phosphate, disodium salt 
hydrate 
Sigma-Aldrich (Munich, Germany) 
D-glucose Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
D-ribose 5-phosphate, disodium salt 
hydrate 
Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
D-seduheptulose 7-phosphate Provided by Dr. Stefan Lüdtke 
D-xylulose 5-phosphate, sodium salt Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Ethylene glycol Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Glycerol  Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 




AppliChem GmbH (Darmstadt, Germany) 




ethanesulfonic acid (HEPES) 
AppliChem GmbH (Darmstadt, Germany) 
Hydrochloric acid (37 %) Th.Geyer GmbH & CoKG (Renningen, 
Germany) 
β-hydroxypyruvate, sodium salt (97 %) Sigma-Aldrich (Munich, Germany) 
Hydroxylamine hydrochloride Sigma-Aldrich (Munich, Germany) 
Imidazol  AppliChem GmbH (Darmstadt, Germany) 
Iron(III) chloride, hexahydrate Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
1,4-Piperazinediethanesulfonic acid (PIPES) AppliChem GmbH (Darmstadt, Germany) 
Kanamycine sulfate Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Magnesium chloride, hexahydrate Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Magnesium sulfate, hydrate Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Medi test glucose test stripes Macherey-Nagel (Düren, Germany) 
Manganese chloride  Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
2-(N-morpholino)ethanesulfonic acid(MES) AppliChem GmbH (Darmstadt, Germany) 
β-Mercapotethanol Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Methanol Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Nicotinamid adenine dinucleotid (NADH) Sigma-Aldrich (Munich, Germany) 
Phosphoric acid (85 %) Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Polyethylene glycol (PEG 6000)  Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Potassium chloride Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
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Roti NC nitrocellulose membrane Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Sodium acetate trihydrate  AppliChem GmbH (Darmstadt, Germany) 
Sodium chloride  AppliChem GmbH (Darmstadt, Germany) 
Sodium dodecylsulfate (SDS)  AppliChem GmbH (Darmstadt, Germany) 
Sulfuric acid Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
N,N,N’,N’, - Tetramethylethylenediamin 
(Temed) 
Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Thiamin chlorid  AppliChem GmbH (Darmstadt, Germany) 
Thiamin diphosphate Sigma-Aldrich (Munich, Germany) 
Trichloroacetic acid Sigma-Aldrich (Munich, Germany) 
3-(Trimethylsilyl) propionic-2,2,3,3-d4 acid 
sodium salt (TSP) 
AppliChem GmbH (Darmstadt, Germany) 
Tris-(hydroxymethyl)-amino methane (TRIS) AppliChem GmbH (Darmstadt, Germany) 
Tryptone AppliChem GmbH (Darmstadt, Germany) 
Whatman chromatography paper GE Healthcare Europe (Munich, Germany) 
Yeast extract AppliChem GmbH (Darmstadt, Germany) 
Yeast extract for high-density fermentation Ohly GmbH (Hamburg, Germany) 
  
Kit systems  
NucleospinTM Plasmid Kit Macherey Nagel (Düren, Germany) 
Quick-ChangeTM Mutagenesis Kit Stratagene (Amsterdam, Netherlands) 
ABI Prism® BigDye Terminator Cycle 
Sequencing Ready Reaction Kit 
Life Technologies GmbH (Darmstadt, 
Germany) 
CloneJet PCR cloning kit MBI Fermentas (St. Leon-Roth, Germany) 
Bac-to-Bac® expression system Invitrogen, (Karlsruhe, Germany) 
BM Chemiluminescence Western Blotting 
Substrate (POD) 
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DNA Marker  
Gene RulerTM 1kb DNA-Ladder MBI Fermentas (St. Leon-Roth, Germany) 
  
Protein Marker  
Unstained Protein Molecular Weight 
Marker 
MBI Fermentas (St. Leon-Rot, Germany) 
Prestained Protein Molecular Weight 
Marker 
MBI Fermentas (St. Leon-Rot, Germany) 
  
Enzymes  
T4-DNA-Ligase  MBI Fermentas (St. Leon Rot, Germany 
Restrictionendonukleases  MBI Fermentas (St. Leon Rot, Germany) 
DNAse  AppliChem GmbH (Darmstadt, Germany) 
Phusion™ High Fidelity- DNA polymerase MBI Fermentas (St. Leon Rot, Germany) 
Triosephosphat isomerase (TIM) + Glycerol 
3-phosphate dehydrogenase (G3P-DH) mix 
Sigma-Aldrich (Munich, Germany) 
Lysozyme  AppliChem GmbH (Darmstadt, Germany) 
PreScission Protease GE Healthcare Europe (Munich, Germany) 
Thrombin from bovine plasma Sigma-Aldrich (Munich, Germany) 




dNTP mix (10 mM) MBI Fermentas (St. Leon Rot, Germany) 
  
Antibodies  
Mouse IgG Penta His Antibody Qiagen (Hilden, Germany) 
Goat IgG anti mouse conjugated with horse 
raddish peroxidase (HRP) 
Jackson ImmunoResearch Europe Ltd., 
(Suffolk, United Kingdom) 
 
 




Micro pulser electroporator BioRad Laboratories GmbH (Munich, 
Germany) 
Incubation shaker, Unitron Infors AG (Bottmingen, Switzerland) 
Biofermenter, Biostat C Sartorius AG (Göttingen, Germany) 
Laminar flow Prettl®-Telsta BioII-A Telstar (Terrassa, Spain) 
Optima LE-80K Ultracentrifuge Beckman Coulter GmbH (Krefeld, 
Germany) 
Universal 320R Hettich GmbH & Co. KG (Tuttlingen, 
Germany) 
AvantiTMJ-25 Centrifuge Beckmann Coulter GmbH (Krefeld, 
Germany) 
AvantiTMJ-30I Centrifuge Beckmann Coulter GmbH (Krefeld, 
Germany) 
AvantiTMJ-20XPI Centrifuge Beckmann Coulter GmbH (Krefeld, 
Germany) 
Centrifuge tubes  Beckmann Coulter GmbH (Krefeld, 
Germany) 
pH-electrode FiveEasy™ FE20 Mettler Toledo (Gießen, Germany) 
Microfluidizer, M-110S Microfluidics (Newton, MA, USA) 
Sonoplus GM 70 Bandelin GmbH & Co. KG (Berlin, 
Germany) 
ÄKTAprime plus GE Healthcare Europe (Munich, 
Germany) 
ÄKTApurifier GE Healthcare Europe (Munich, 
Germany) 
HisPrep FF 16/10 GE Healthcare Europe (Munich, 
Germany) 
Sephadex 200 GE Healthcare Europe (Munich, 
Germany) 
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HiPrep 26/10 desalting GE Healthcare Europe (Munich, 
Germany) 
Uno Q&S ion exchange column BioRad (Munich, Germany) 
Superdex 200 10/30 Analytical gel filtration 
column 
GE Healthcare Europe (Munich, 
Germany) 
Superloop (10 mL, 50 mL, 150 mL) GE Healthcare Europe (Munich, 
Germany) 
Gel filtration standard BioRad Laboratories GmbH (Munich, 
Germany) 
Vivaspin concentrator 6, 20 mL (30000, 
50000 MWCO) 
Sartorius AG (Göttingen, Germany) 
Electrophorese device, EV 231 Consort bvba (Turnhout, Belgium) 
Mini-PROTEAN® Tetra cell system BioRad Laboratories GmbH (Munich, 
Germany) 
SE250 small format vertical Electrophoresis 
system 
Hoefer Inc., (MA, USA) 
Thermocylcer, TProfessional standard 96 well 
gradient 
Whatman Biometra (Göttingen, 
Germany) 
Gel documentation chamber raytest Ida Herolab (Wiesloch, Germany) 
Sterile filters, 0.22 µM VWR International GmbH (Darmstadt, 
Germany) 
Precision cuvettes, suprasil Hellma GmbH & Co.KG (Mühlheim, 
Germany) 
UV-Vis spectrometer, V-650 Jasco GmbH, (Groß-Umstade, Germany) 
ITC-system, ITC200 GE Healthcare Europe (Munich, 
Germany) 
Filters for NMR samples, 0.45 µM GE Healthcare Europe (Munich, 
Germany) 
ARX 400 MHz Bruker Biospin GmbH (Karlsruhe, 
Germany) 
Stopped-flow system SX.20 Applied Photophysics Ltd., UK 
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X-ray MM-007 rotating-anode generator, 
Micromax 007- HF X-stream 2000, R-AXIS 
IV++ imaging-plate system 
Rigaku Corp., (MI, USA) 
 
2.3 Programs 
SigmaPlot 11.0 Systat Software Inc. (Erkrath, Germany) 
Origin 7 OriginLab Corp., MA, USA 
Multalin http://multalin.toulouse.inra.fr/multalin/ 88 
ESPRIPT http://espript.ibcp.fr/ESPript/ESPript/ 89 
PYMOL DeLano Scientific LLC 
MestreNova Mestrelab research (Santiago de 
Compostela, Spain) 
Kaleidagraph Synergy Software, NJ, USA  
 
2.4 Media 
Lysogeny-broth-medium (LB) 90 
Tryptone/Peptone from casein (pancreatic digested) 0.1 % (w/v) 
Yeast extract        0.05 % (w/v) 
NaCl        0.1 % (w/v) 
 
Super-broth-medium (SB) (3xLB) 
Tryptone/Peptone from casein (pancreatic digested) 0.3 % (w/v) 
Yeast extract       0.15 % (w/v) 
NaCl        0.3 % (w/v) 
 
LB-plates 
1.5 % (w/v) Agar was added to LB-medium, as well as the required antibiotic 








Kanamycine:   35 μg/mL 
Carbenicillin:   100 µg/mL 
 
2.5 Bacterial strains 
Table 1: Used bacterial strains 
Organism Strain Genotype Reference Supplier 









E. coli BL21 Star F-ompT hsdSB(rB
-
mB



























Table 2: Used vectors 
Vector Selection marker Supplier 
pET28a Kanamycine Novagen (Schwalbach/Ts, 
Germany) 
pMK-RQ Kanamycine Geneart (Regensburg, 
Germany) 
pET-SUMO Kanamycine Invitrogen (Karlsruhe, 
Germany) 
pCOLD Carbenicillin TaKaRa Bioscience Inc. 
(Otsu, Japan)) 
 
2.7 Utilized primers 
 
Sequencing primers  
T7 promotor TAATACGACTCACTATAGGG 
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Mutagenesis primers  
pBAC sense GGCCATGCGGATCCATGGCGGATGCCGAAGCG 
pBAC antisense GGCCATGCGGATCCATGATGGCAAATGATGCC 
BbXFPK E437Q sense GCATCTTCGGACCGGACGAAACCGCTTCCAACCGCC 
BbXFPK E437Q antisense GGCGGTTGGAAGCGGTTTCGTCCGGTCCGAAGATGC 
hTKT deletion sense CGTTTTGTTCTGAGCAAAAAACAGGCGTTTACCGATGTG 
hTKT deletion antisense CATCGGTAAACGCCTGTTTTTTGCTCAGAACAAAACGATCG 
 
2.8 Methods 
2.8.1 Escherichia coli cultivation 
Escherichia coli (E. coli) strains used for this thesis were either cultivated on solid or 
liquid LB-media. Precultures were incubated shaking in LB-medium at 37 °C and 
200 rpm. Expressioncultures grew in SB-medium over night at 12 °C and 180 rpm in 
baffled flasks. Plasmid-containing clones were selected by choosing the required 
antibiotics. Carbenicillin was used for all pCOLD-TKTL1 and 2 constructs, kanamycine for 
all pET28a derived ones, namely the full–length TKT, TKTΔ38, pETSUMO-TKTL1, 
pETSUMO-TKTL2 and XFPK of Bifidobacterium breve. 
 
2.8.2 Transformation of E. coli 
Preparation of the desired E. coli strains and transformation was performed as described 
by Inoue et al. 92. 
 
2.8.3 Isolation of plasmid DNA 
For plasmid isolation 5 mL LB-medium were incubated with the desired plasmid-
containing E.coli strain and incubated shaking over night at 37 °C and 200 rpm. Plasmid 
preparation was performed according to the Nucleospin™ Plasmid Kit (Macherey-Nagel). 
Obtained plasmids were stored at -80 °C. 
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2.8.4 Amplification of specific DNA fragments and site-directed 
mutagenesis by polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify desired DNA-fragments as well as 
to construct selected variants. For all applications Phusion™ High Fidelity DNA-
polymerase was used according to the manufacturers’ manual (MBI Fermentas [St. Leon 
Rot, Germany]). 
 
2.8.5 DNA-concentration determination 
Concentration of double stranded DNA was determined spectroscopically by using the 
absorption at 260 nm. Correlation of absorption and DNA-concentration is as follows: 
A260 = 1 = 50 µg/mL pure ds DNA 
 
2.8.6 DNA-restriction 
DNA-restriction was performed according to the manufacturer’s manual of the used 
endonucleases (MBI Fermentas [St. Leon-Roth, Germany]). 
 
2.8.7 Separation of DNA-fragments by agarose-gelelectrophoresis 
Agarose-gelelectrophoresis was used for separation and size determination of DNA-
fragments. For that purpose 1 % agarose gels (w/v) were used. Before electrophoresis 
sample buffer (EDTA 250 mM, SDS 0.1 % [w/v], glycerol 40 % [w/v], bromophenol blue 
0.025 % [w/v], xylenecyanol 0.025 % [w/v]) was added to the samples. GeneRuler™ 
DNA-Ladder served as size standard. Electrophoresis was carried out at 120 V for 
50 minutes in 1xTAE buffer (TRIS HCl [40 mM], acetic acid [20 mM], EDTA [1 mM], pH 7). 
Gels were stained in an ethidiumbromide solution (2 µg/mL) for 10 minutes. 




DNA ligation was performed by use of T4 DNA-ligase according to the manufacturers’ 
manual (MBI Fermentas [St. Leon-Roth, Germany]). 
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2.8.9 CloneJet PCR cloning kit 
The CloneJet PCR cloning kit was used to ligate blunt end PCR products into the pJET 
amplification vector. This was carried out as described in the manufacturers’ manual 
(MBI Fermentas [St. Leon-Roth, Germany]). 
 
2.8.10 Generation of a hTKT deletion construct by overlap extension PCR 
An overlap extension method was used to create the 38 amino acid deletion variant 93. 
This was carried out by using the Phusion™ High Fidelity DNA polymerase system. The 
hTKT sense and antisense deletion primers listed in the primer list were used as well as 
T7 sense and antisense primers. In a first step the two domains intended to be fused 
(aminoacids 1–75 and 114–623) were amplified individually by using the following 
primer combinations: T7 forward/deletion reverse and T7 reverse/deletion forward. In a 
subsequent PCR reaction the amplicons were fused by usage of T7 forward and T7 
reverse primers. The shortened hTKT construct was cloned into the amplification 
plasmid pJET (Fermentas) and transferred as NcoI/XhoI fragment into pET28a expression 
vector. 
 
2.8.11 DNA sequencing 
DNA-sequencing was used to confirm the correctness of the used DNA-constructs. 
Sequencing was either performed with the ABI Prism BigDye Terminator Cycle 
Sequencing Ready Reaction Kit, or by a company (Seqlab, Göttingen, Germany). 
Amplicons generated with the BigDye Sequencing Kit were analyzed for their sequence 
by courtesy of Andreas Nolte (Department of Developmental Biochemistry, Georg-
August-University Göttingen). 
 
2.8.12 Insect cell culture 
Expression of TKTL1 and 2 was performed by use of the Bac-to-Bac® expression system 
(Invitrogen, [Karlsruhe, Germany]). The Spodoptera frugiperda derived cell lines Sf-9 and 
Sf 21 as well as the Trichoplusia ni derived cell line Hi5™ were used according to the 
manufacturers’ manual. Baculovirus constructs carrying the genes of TKTL1 and 2 were 
previously generated as described in the manual. All cell cultural experiments were 
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performed by courtesy of Michael Franke (Department for Molecular Structural Biology, 
Georg-August-University Göttingen). 
 
2.8.13 Generation of pCOLD-TKTL1 and 2 fusion constructs 
The genes encoding for codon optimized TKTL1 and 2 were amplified by use of Phusion 
DNA-polymerase as described above. The amplicons were fused as KpnI/XhoI fragments 
into the pCOLD expression plasmid in-frame harboring an N-terminal trigger-
factor/hexahistidine tag. 
 
2.8.14 High density fermentation 
To generate high amounts of TKTL1/2 high density fermentation was carried out in a 
biofermenter. Two 200 mL overnight precultures containing 35 µg/mL kanamycine were 
generated from a single colony of E coli BL21 Star harboring either the pETSUMO-TKTL1 




300 g yeast fermentation extract 
3 g NH4Cl 
30 g glucose 
4 g MgSO4 
66 g K2HPO4 
1 mL Antifoam 204 
1 mg/mL thiamin dichlorid 
35 µg/mL kanamycine 
The fermentation batch was stirred at 400-1500 rpm and aerated with a flow of 3–
24 L/min of air, to maintain an O2-level of 30 % at a temperature of 37 °C. A neutral pH 
was established by computer controlled addition of 10 % NaOH or 10 % H3PO4. After 
glucose was consumed (verified by medi test glucose test stripes) feeding was started by 
adding a proper amount of feeding solution into the fermentation batch until the 
desired OD600 was reached (~60-80). 





600 g yeast fermentation extract 
600 g glucose 
add to 2 L with ddH2O 
 
TKTL1 and 2 expression was induced after cooling the fermenter down to 18 °C by 
addition of 100 µM IPTG. After 12 hours the cells were harvested by centrifugation 
(2921 g, 30 min, 4 °C), the yield was in the range of 1.5-2 kg of wet cell material. 
 
2.8.15 Expression and purification of full length hTKT and the Δ38 deletion 
variant 
The pET28a vector encoding for C-terminal His-tagged full length human transketolase 
was provided by Dr. Kathrin Schröder-Tittmann (Department for Bioanalytics, Georg-
August-University Göttingen). The full length construct and the Δ38 deletion variant of 
human transketolase were transformed into E. coli BL21 Star cells by the method of 
Inoue 92. Transformed cells were grown on LB/Agar plates containing 35 μg/mL 
kanamycine over night at 37 °C. A single colony was used to inoculate 200 mL of an 
overnight culture and expression was carried out as described in section 2.8.1. 
For protein purification, 20 g of cells were thawed and resuspended on ice in 60 mL of 
buffer containing 20 mM TRIS-HCl pH 7.6, 500 mM NaCl, 20 mM imidazole, 1 mM CaCl2 
and 100 μM ThDP. Moreover, DNase (5 μg/mL), MgCl2 (1 mM), Lysozyme (0.2 mg/mL) 
and PMSF (1 mM) were added. The suspension was stirred on ice for 30 min. Cells were 
disrupted by repeated passages through a microfluidizer. Cell debris was removed by 
centrifugation at 54000 x g for 30 min at 4 °C. The supernatant was loaded onto a 
HisPrep FF 16/10 column previously equilibrated with 20 mM TRIS-HCl, pH 7.6, 500 mM 
NaCl, 20 mM imidazole, 1 mM CaCl2 and 100 μM ThDP. TKTΔ38 was eluted with a linear 
gradient (0-100%) of elution buffer (20 mM TRIS-HCl, pH 7.6, 500 mM NaCl, 1 mM CaCl2, 
100 μM ThDP and 300 mM imidazole) over a total volume of 20 column volumes. 
Fractions containing TKTΔ38 were pooled and loaded onto a HiPrep™ 26/10 desalting 
column equilibrated with 50 mM glycylglycine, pH 7.6 containing 1 mM CaCl2, 100 μM 
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ThDP and 500 mM NaCl. Finally, the protein concentration was adjusted to 15-25 mg/mL 
by ultra filtration using a microconcentrator (VIVASPIN, Sartorius) with a molecular 
weight cut-off of 50000 at 4 °C. Protein homogeneity was judged by SDS-PAGE analysis. 
 
2.8.16 Expression and purification of full length TKTL1 and 2 
The pCOLD vector encoding for N-terminal trigger factor/His-tagged full length human 
transketolase-like protein 1 and 2 were transformed into E. coli BL21 Star cells by the 
method of Inoue 92. Transformed cells were grown on LB/Agar plates containing 
100 μg/mL carbenicillin over night at 37 °C. A single colony was used to inoculate 200 mL 
of an overnight culture and expression was carried out as described in section 2.8.1 . 
For protein purification of the pCOLD- and the pETSUMO-constructs, 20 g of cells were 
thawed and resuspended on ice in 60 mL of buffer containing 20 mM TRIS-HCl pH 8, 
500 mM NaCl, 20 mM imidazole, 1 mM CaCl2 and 200 μM ThDP. Moreover, DNase (5 
μg/mL), MgCl2 (1 mM), Lysozyme (0.2 mg/mL) and PMSF (1 mM) were added. The 
suspension was stirred on ice for 30 min. Cells were disrupted by repeated passages 
through a microfluidizer. Cell debris was removed by centrifugation at 54000 g for 
30 min at 4 °C. The supernatant was loaded onto a HisPrep FF 16/10 previously 
equilibrated with 20 mM TRIS-HCl, pH 8, 500 mM NaCl, 1 mM CaCl2 and 200 μM ThDP. 
Bound proteins were eluted with a one step gradient (0-100 %) of elution buffer (20 mM 
TRIS-HCl, pH 8 containing 1 mM CaCl2, 200 μM ThDP, 500 mM NaCl and 300 mM 
imidazole). Fractions containing the desired protein were pooled and loaded onto a 
HiLoad™ 16/60 superdex 200 pg gel filtration column equilibrated with 50 mM 
glycylglycine, pH 7.6 containing 500 mM NaCl, 1 mM CaCl2 and 200 μM ThDP. Finally, the 
protein concentration was adjusted to 15-25 mg/mL by ultra filtration using a 
microconcentrator (VIVASPIN, Sartorius) with a molecular weight cut-off of 50000 at 
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2.8.17 Expression and purification of xylulose 5-phosphate/fructose 6-
phosphate phosphoketolase (XFPK) from Bifidobacterium breve 
The pET 28a vector harboring N-terminally His-tagged XFPK of B. breve was kindly 
provided by Prof. Dr. Shinya Fushinobu (University of Tokyo, Japan). Expression and 




Homogeneity of purified proteins was judged by one dimensional SDS-PAGE according to 
Laemmli 94. 20 µL of a sample, with a concentration of 0.4 mg/mL, was mixed with 20 µL 
of 2xLaemmli buffer, heated at 98 °C for 5 minutes and used for electrophoresis. Gels 
containing 12 % acrylamid were run at 30 mA for 50 minutes. 
 
2.8.19 Protein concentration determination according to Bradford 
A colometric method according to Bradford was used for protein concentration 
determination 95. By use of a bovine serum albumin standard solution a reference linear 
slope was generated. Absorption of the colored protein-bradford reagent (methanol 5 % 
[v/v], acetic acid 10 % [v/v] and coomassie brilliant blue G250 [0.25 % [w/v]) complex 
was determined at a wavelength of 595 nm. 
 
2.8.20 Detection of the proteins of interest by western bloting 
Western blot analysis was performed to verify TKTL1 and 2 expression in baculovirus 
infected insect cell lines. After SDS-PAGE of the desired samples as described above, 
proteins were blotted onto a nitrocellulose membrane in a Mini-PROTEAN® Tetra cell 
system. Blotting was performed for 1 h at 350 mA and 4 °C in blotting buffer (TRIS base 
25 mM, glycine 192 mM and methanol 20 % [v/v]). Unspecific binding sites were blocked 
with 3 % (w/v) dry milk powder in TBS-T buffer for 1 h (TRIS base 50 mM, NaCl 150 mM 
Tween20 0.05 % [v/v], pH 7.6. The following incubation with primary antibody (mouse 
IgG anti pentaHistidine 1:10000 in TBS-T) was performed over night at 4 °C. Primary 
antibody was removed by three washing steps with TBS-T buffer, followed by secondary 
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antibody (Goat IgG anti mouse conjugated with horse raddish peroxidase (HRP), 1:10000 
in TBS-T) incubation for 2 h at 4 °C. After three more washing steps chemiluminescence 
reaction was performed by use of the BM Chemiluminescence Western Blotting 
Substrate (POD) according to the manufacturers’ manual (F.Hoffmann-La Roche AG, 
[Basel, Switzerland]). The blot was exposed to a roentgen film in a photo cassette for 
different time points (1-120 sec). 
 
2.8.21 Analytical gel filtration 
Analytical gel filtration experiments were carried out on an ÄKTA Purifier HPLC-system 
by loading 200 µL of protein solution (4 mg/mL) on a Superdex 200 10/30 column. 
Oligomerization degree was estimated by use of a gel filtration-standard (BioRad 
Laboratories GmbH [Munich, Germany]). 
 
2.8.22 Coupled optical enzymatic assay 
The enzymatic activity of TKTΔ38, full-length TKT, TKTL1 and TKTL2 for conversion of 
physiological substrates X5P and R5P into products G3P and S7P was measured in a 
coupled spectrophotometric assay using the auxiliary enzymes triosephosphate 
isomerase (TPI) and sn-glycerol-3-phosphate:NAD+2-oxido-reductase (G3PDH) (Figure 
15) 96. This assay detects formation of the product G3P that derives from TKT-catalyzed 
cleavage of substrate X5P. The concomitant oxidation of NADH was followed 
spectrophotometrically at 340 nm in 50 mM glycylglycine, pH 7.6 containing 500 mM 
NaCl at 30 °C. The assay contained as final concentration 220 μM NADH, 3.6 units of 
TIM/G3PDH enzyme mix, 1 mM thiamine diphosphate, 1 mM CaCl2, 5 mM of X5P and 
R5P, and varied concentrations of TKTΔ38 and full-length TKT (0.05 – 2 mg/mL). 
 
Figure 15: Coupled enzymatic assay 
for conversion of X5P and R5P by 
transketolase. 
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2.8.23 Circular dichroism spectroscopy 
2.8.23.1  Far-UV CD-based secondary structure element analysis 
For analyzing secondary structure contents of proteins, far UV circular dichrosim (CD) 
was used 97. Spectra of full length TKT as well as TKTΔ38, TKTL1, TKTL2 and XFPK (wt and 
variants) were recorded at 20 °C in a 1 mm quartz cuvette by usage of a CD 
spectrometer equipped with a peltier temperature control element. The protein 
concentration was adjusted to 0.1 mg/mL in 50 mM sodium phosphate buffer, pH 7.6 
containing 2.5 mM MgCl2 and 100 µM ThDP. To prevent protein aggregation of TKTΔ38, 
the buffer additionally contained 500 mM NaCl. The buffer corrected spectra were 
converted to mean residue ellipticity 
 
[θ] MRW ,λ =
𝑀𝑅𝑊 ∗  𝜃λ
10 ∗ 𝑑 ∗ 𝑐
                                                                                                [𝟏] 
 
with Θ as the measured ellipticity at the given wavelength λ, the pathlength d, the 
concentration c (in g/L) and MRW which is the molecular weight of the corresponding 
protein divided by its amino acid chain length – 1. The unit of the mean residue 
ellipticity is deg * cm2 * dmol-1. 
The program CDNN 98 was used to analyze secondary structure contents. The stability of 
the proteins was investigated by thermal denaturation at a wavelength of 222 nm within 
a temperature range of 293-367 K. The heating rate was adjusted to 1 K/min, the data 
interval was set at 0.5 K at an accumulation time of 12 sec. Spectra were recorded 
before (at 293 K) and after (367 K and 293 K) thermal denaturation. Transition point of 
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      y=
 (yf+mf ∙T)+(yu+mu ∙T)∙ exp   
∆Hm
RT  ∙  
 T-Tm
Tm
   
1+ exp   
∆Hm




                                              [2]       
 
y  =  Circular dichroism signal at 222 nm 
yf, yu  = Intercepts of pre- and posttransition baselines 
mf, mu  = Slopes of pre- and posttransition baselines 
T  = Temperature in Kelvin 
Tm  = Midpoint of the thermal unfolding curve 
ΔHm  = Enthalpy change for unfolding at Tm 
R  = Gas constant 
 
This equation was described as characteristic for reversible folding proteins. Since none 
of the investigated proteins showed such behaviour, absolute transiton points can not 
be determined. A comparison of the stability of the respective variants is nevertheless 
possible. 
 
2.8.23.2  Near-UV CD-based detection of a cofactor caused charge transfer absorption 
band 
All so far known TKTs give rise to a negative CD signal centered around 320 nm which 
reflects a charge transfer interaction between the aminopyrimidine- and the thiazolium 
potion of the cofactor (AP signal) 100 101. We investigated full length TKT as well as 
TKTΔ38, TKTL1, TKTL2 and XFPK (wt and variants) for cofactor binding. For that purpose 
near-UV spectra were recorded in a 10 mm quartz cuvette at 20 °C. The buffer corrected 
spectra were recorded either in 50 mM glycylglycine buffer, pH 7.6 (for TKT, TKTΔ38, 
TKTL1 and 2) or in 20 mM HEPES buffer, pH 7.2 (for wt XFPK and variants) at a protein 
concentration of 1-2 mg/mL, the scanning range was from 400–290 nm. To elucidate 
dynamical changes of the respective charge/tautomeric states of the bound ThDP 
cofactor, signal spectra were recorded with different pH-values. The pH was adjusted by 
dissolving XFPK (1mg/mL) in MES/PIPES/TRIS buffer (20 mM each) with the desired pH-
values ranging from 6-9. 
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2.8.24 Cofactor binding studies by 1H NMR spectroscopy 
To verify whether the TKTΔ38 variant, TKTL1 and TKTL2 contained tightly bound ThDP 
cofactor, acid quench/NMR experiments were performed. For that purpose 400 µL of 
the corresponding freshly prepared protein was dialyzed against cofactor-free buffer. 
Afterward 400 µL of protein (7.5 mg/mL  in 50 mM glycylglycine buffer, pH 
7.6 containing 500 mM NaCl) were quenched by addition of 200 µL quench solution 
(650 µL D2O, 250 µL TCA 50 % [w/v] in H2O and 100 µL HCl 37%). The denatured protein 
was pelletized by centrifugation (10 min, 4 °C and 15000 rpm) and the supernatant 
filtered through a 0.22 µm nylon-membrane filter. NMR-samples were measured by 
Cindy Wechsler (Department for Bioanalytics, University of Göttingen) or Prof. Dr. Kai 
Tittmann (Department for Bioanalytics, University of Göttingen) on a 400 MHz Bruker 
NMR-spectrometer with 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid as internal standard 
at desired conditions 102. 
 
2.8.25 Covalent reaction intermediate analysis by acidic quench 1H NMR 
spectroscopy 
1H NMR acidic quench spectroscopy was established to analyze microscopic steps of 
ThDP-dependent catalysis 103. The desired enzymes were incubated with the substrate of 
choice at pre steady-state or steady-state conditions and quenched by a strong acidic 
solution after desired time points. The acid-stable ThDP-intermediates were analyzed by 
1H NMR spectroscopy. By this method a qualitative analysis of the occurring 
intermediates, starting from the Michaelis complex up to the different cleavage-raised 
intermediates can be performed. 
For detection of the different intermediates present in XFPK, the wild-type enzyme and 
several variants were incubated with F6P solely, or in presence of the second substrate 
phosphate. To prevent falsification from free ThDP in the buffer, the enzyme was 
dialyzed against cofactor-free buffer. A typical experiment was performed by incubating 
200 µL XFPK-solution (15 mg/mL) with 200 µL of 50 mM F6P, or F6P/Pi (all in 20 mM 
HEPES-NaOH, pH 7.2) at room temperature. After a few seconds the reaction was 
quenched by addition of 200 µL quench solution (650 µL D2O, 250 µL TCA 50 % [w/v] in 
H2O and 100 µL HCl 37%). The denatured protein was pelletized by centrifugation 
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(10 min, 4 °C, and 15000 rpm) and the supernatant filtered through a 0.22 µm nylon-
membrane filter. NMR-samples were measured by Cindy Wechsler (Department for 
Bioanalytics, University of Göttingen) or Prof. Dr. Kai Tittmann (Department for 
Bioanalytics, University of Göttingen) on a 400 MHz Bruker NMR-spectrometer with 3-
(trimethylsilyl) propionic-2,2,3,3-d4 acid as internal standard at desired conditions 
102. 
 
2.8.26 Analysis of XFPK catalysis derived acetate and d4-acetate by 
product 1H NMR spectroscopy 
1H NMR spectroscopy was used to analyze H/D exchange at the terminal methyl group 
of acetate derived from XFPK driven F6P conversion. A typical experiment contained 
2 mg/mL of the desired enzyme in 50 mM HEPES buffer (pH 7.2) containing 1 mM MgCl2 
and 200 µM thiamine diphosphate. F6P were dissolved in the same buffer and added to 
a final concentration of 5 mM. Reaction was incubated at 37 °C for 10 min. The reaction 
was either performed in aqueous buffers or in deuterium oxide based buffers. Protein 
was separated by ultra filtration using a microconcentrator (VIVASPIN, Sartorius) with a 
molecular weight cut-off of 5000 at 4 °C. Flow through was analyzed for products by 
1H NMR spectroscopy by Prof. Dr. Kai Tittmann (Department for bioanalytics, University 
of Göttingen, Germany) on a 400 MHz Bruker NMR-spectrometer with 3-(trimethylsilyl) 
propionic-2,2,3,3-d4 acid as internal standard at desired conditions. 
 
2.8.27 Determination of XFPK activity by the hydroxamate assay 
Activity of wt XFPK and selected variants was analyzed by monitoring the amount of 
formed acetyl phosphate in form of a colored compound as described earlier 80 104 105. 
 
2.8.28 Calorimetric based enzyme kinetics 
A calorimetric based method was used for determination of kinetic parameters of XFPK 
as described earlier 106. For the kinetic measurements of XFPK different variants and 
substrates were used. In a general experiment XFPK at varying concentrations in HEPES 
buffer (20 mM, pH 7.2) containing 1 mM MgCl2, 50 mM Na2HPO4 and 200 µM ThDP was 
incubated with different substrate concentrations. The exact specified parameters of the 
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reactants and the Microcal ITC200 instrument settings are depicted in the corresponding 
graphs in the results part of this work.  
 
2.8.29 Product analysis via mass spectrometry 
Sugarphosphate derived products of a putative enzymatic TKTL1 and TKTL2 activity were 
measured by mass spectrometry. A typical experiment contained 2 mg/mL of the 
desired enzyme in 50 mM glycyl-glycine buffer (pH 7.6) containing 1 mM CaCl2 and 
100 µM ThDP. X5P, R5P and Coenzyme A were dissolved in the same buffer and added 
to a final concentration of 1 mM. Reaction was incubated at 37 °C for 10 min. Protein 
was separated by ultra filtration using a microconcentrator (VIVASPIN, Sartorius) with a 
molecular weight cut-off of 5000 at 4 °C. Flow through was analyzed for products by 
courtesy of Dr. Cornelia Herfurth (Department for Plant Biochemistry, University of 
Göttingen) via nano electronspray ionisation mass spectrometry. For a measurement the 
product containing flow through was dissolved in 85 % (v/v) methanol, 15 % (v/v) 
acetonitril and 0.1 % (v/v) acetic acid. After acidification of the sample the molecules 
undergo ionization when transferred into the electron spray ionization device of the 
mass spectrometer. The generated ions were trapped and analyzed according to their 
mass over charge (m/z) ratio. Moreover it was possible to to analyze ions with an m/z 
ration of interest by collision induced dissociation (CID) in helium gas followed by 
daughter ion generation. Characteristic daughterinos for possible products are 
phosphate (97 m/z), G3P (170.1 m/z), X5P (229.1 m/z), R5P (229.1 m/z) as well as 
Coenzyme A (768 m/z) and acetyl Coenzyme A (810 m/z) with their respective 
fragmentation product with a m/z of 408 107 (Figure 16). 





2.8.30 Monitoring XFPK reaction intermediates by stopped flow 
absorbance spectroscopy 
Stopped-flow and sequential stopped-flow/UVvis measurements of XFPK were 
performed to characterize fast kinetic events. Experiments were performed by use of a 
photo diode array. Experiments were performed at 18 °C with an optical path length of 
1 cm. Single mixing experiments were carried out by use of the photo diode array with 
mixing ratios of 1:1. 
To analyze if certain reaction intermediates are already formed after addition of only the 
first substrate F6P without anorganic phosphate sequential stopped flow experiments 
were performed. Premixture containing high amounts of enzyme and F6P were mixed 
manually. In single mixing experiments the premix and a phosphate solution were used 
as described above. The respective buffer-, cofactor- and enzyme concentrations of the 
experiments are depicted in the in the figures of the results part. 
 
Figure 16: Expected m/z ratios for the used sugar phosphate and Coenzyme A substrates and products. 
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2.8.31 XFPK E437Q crystallization and data processing 
Crystallization of the XFPK E437Q variant was performed by the hanging drop vapor 
diffusion method according to Suzuki et al. 80. XFPK variant E437Q was purified as holo 
enzyme and adjusted to a protein concentration of 20–30 mg/mL in 5 mM HEPES-NaOH 
pH 7.2, 0.25 mM MgCl2 and 25 µM ThDP. 1.5 µL of protein solution was mixed in a 1:1 
ratio with reservoir solution containing 20–30 % PEG 6000 (w/v) in BICINE buffer (0.1 M, 
pH 9) at 18 °C. Crystals grew within a few days at 18 °C. 
For data collection crystals were soaked in 24 % PEG 6000 (w/v) in BICINE (0.1 M, pH 9) 
containing 20 % (v/v) ethylene glycol. Soaked crystals were flash frozen and stored in 
liquid nitrogen. Soaking experiments were performed with F6P at different 
concentrations (27 mM and 54 mM) as reported elsewhere for varying periods of time 
79. Crystals were tested for preliminary diffraction quality in-house on a nitrogen 
cryostream (130-140 K, XSTREAM2000, Rigaku/MSC, Japan) with an R-AXIS IV++ imaging-
plate system (Rigaku/MSC, Japan) using CuKα radiation generated by a Rigaku MM-007 
rotating-anode generator. High resolution data sets were collected by Dr. Piotr 
Neumann (Department for Molecular Structural Biology, University of Göttingen, 
Germany) at the Positron-Elektron-Tandem-Ring-Anlage (Petra) of the german electron 
synchrotron facility (DESY) in Hamburg. 
Processing of the collected data was performed with XDS 108 by courtesy of Dr. Piotr 
Neumann. The obtained models were iteratively refined and improved by use of PHENIX 
109 and final validation was performed with MOLPROBITY. Restraints for additional ligands 
(ThDP-intermediates, buffer molecules and substrates) were generated with the 
PRODRG server 110. For collection- and structure refinement statistics see Appendix. The 
final model was validated with COOT 111 and electron density maps (|Fo|-|Fc|, 2|Fo|-
|Fc|) were generated with PHENIX. Preperation of the final figures was performed with 






3.1 A Δ38 deletion variant of TKT as a minimal model for analysis of a 
putative TKTL1 function 
3.1.1 Generation and purification of native TKT and TKTΔ38 
The 38 amino acid sequence missing in TKTL1 compared to TKT was removed by an 
overlap extension PCR based method 93. The genes, which are optimized for codon 
usage in E.coli, were expressed by a protocol previously established for TKT 50. Full 
length TKT and TKTΔ38 were purified to homogeneity in the milligram scale (~40 g 
protein form a 20 g cell pellet) (Figure 17). First 
purifications based on the established protocol 
showed that the deletion variant undergoes 
precipitation under low salt conditions (50 mM glycyl 
glycine, pH 7.6 containing 1 mM CaCl2 and 100 µM 
ThDP). Sodium chloride at concentrations above 
500 mM turned out to be a suitable additive to 
prevent denaturation of the variant. Therefore, all 
further purifications were performed with 500 mM 
sodium chloride in all buffers. 
 
 
3.1.2 Analysis of secondary structure and thermal stability of native TKT 
and TKTΔ38 
The increased tendency of the deletion variant to precipitate under low salt buffer 
conditions indicates a lower stability in comparison to full legth TKT. Therefore a CD 
based secondary structure analysis was performed to enlight structural changes and the 
decreased stability in the variant in comparison to the wild type. 
The CD spetrum recorded for full length TKT corresponds to a typical (α/β)-protein with 
two negative bands at 208 nm and 220 nm, and a positive signal at 195 nm. By using the 
CDNN software the α-helical fraction was estimated to be 35 % whereas the β-sheet 






Figure 17: SDS-PAGE of purified native 
TKT and TKTΔ38. As expected, the deletion 
variant migrates with a smaller apparent 
molecular weight than the wt enzyme. (1) 




derived from crystallographic data (36 % α-helices and 16 % β-sheets estimated by use 
of the program PROMOTIF, pdb code: 3MOS). 
Due to the strong CD absorbance of chlorid ions the CD spectrum of TKTΔ38 is limited to 
wavelengths above 200 nm (Figure 18). Despite this restriction the overall quality of the 
spectrum is good. Unstructured elements - which would contribute to a strong negative 
absorption around 190 nm - could not be detected. Noteworthy is a smaller absorption 
at 222 nm compared to TKT corresponding to a loss of α-helical content. This is an 
expected finding since the deleted 38 amino acids form two short helices 50. The CDNN 
based analysis of TKTΔ38 is in good agreement with this result because the calculated α-
helical part is lowered to 31 % whereas the β-sheet content is only slightly affected 
(17 %). A sample CD spectrum of secondary structure contribution to ellipticity signals 
can be found in the appendix. 
Next, the stability of both proteins was analyzed by thermal unfolding which turned out 
to be an irreversible process in both cases (Figure 18). Unfolding of TKT usually followed 
a one phase transition with a transition point at 345 K (data not shown). On the 
contrary, TKTΔ38 was not stable under the same conditions and precipitated 
immediately. To overcome this restriction 500 mM NaCl were added and TKTΔ38 turned 
out to be stable at 293 K. The apparent melting temperature for this variant was ~317 K. 
In comparision, full length TKT showed a two phase transition under high salt conditions 
- a minor one at 326 K and a major one at 337 K. 
Temperature (K)






















































Figure 18 Far-UV spectra and thermal unfolding of native TKT and the TKTΔ38 deletion variant. (A) Far-UV CD 
spectra of native TKT and the TKTΔ38 deletion variant were recorded at a protein concentration of 0.1 mg/mL in 
50 mM sodium phosphate buffer, pH 7.6 containing 500 mM NaCl, 2.5 mM MgCl2 and 100 µM ThDP at 20 °C. (B) 




3.1.3 Transketolase activity of TKTΔ38 
Enzymatic activity measurements of TKTΔ38 were performed as outlined in section 
2.8.22. The substrates X5P and R5P are converted by all known TKTs to S7P and G3P. For 
the activity assay G3P is further processed by auxilliary enzymes (TPI and G3PDH) linked 
to the oxidation of NADH. As control native TKT was used. Since the deletion variant is 
unstable under low salt conditions the reaction batch contained 500 mM sodium 
chloride to prevent enzyme precipitation. In high salt buffer native TKT exhibited a 
slightly lowered enzymatic activity in comparison to low salt conditions as reported 
earlier (~ 1 U/mg versus 2.7 U/mg (Figure 19) 50. Contrary, no enzymatic activity could be 
detected for the TKTΔ38 variant, even at an enzyme concentration of 2 mg/mL. Whether 
the lack of enzymatic activity is caused by the absence of catalytically essential amino 


































Figure 19: Steady-state kinetic of 
enzymatic activity of native TKT as well 
as the TKTΔ38 variant. Conversion of 
native substrates X5P and R5P (2 mM 
each) to S7P and G3P which is linked to 
the consumption of NADH was 
monitored at 340 nm. No enzymatic 





3.1.4 Analysis of cofactor binding competence of ∆38 TKT by near-UV CD 
spectroscopy 
Binding of the ThDP cofactor to TKTΔ38 as well as TKT was analyzed to address the 
question, whether the lack of enzymatic acticity in the deletion variant is caused by 
imprecise or absent cofactor binding. All so far characterized TKTs show a characteristic 
absorbance pattern in near-UV CD which were assigned to different tautomerization and 
ionization states of the aminopyrimidine ring system of ThDP (see introduction). 
TKTs reveal a broad, negative signal between 320 to 350 nm when complexed with 
ThDP 100 101. Indeed, such a negative signal at 325 nm can be detected in TKT wild type, 
confirming previous results 112 113 (Figure 20). No such signal was observed in the 
deletion variant under the same conditions, as well as after adding a huge excess of both 
of the cofactors to the buffer (up to 10 mM ThDP and Ca
2+). This outcome either 
corresponds to the absence of enzyme bound ThDP in the deletion variant or an affected 
chemical state of the bound ThDP resulting in spectroscopically silent cofactor. 
To rule out that ThDP is bound in a spectroscopically silent state a 1H NMR spectroscopic 
approach was used. For that purpose the enzyme is initially saturated with cofactor and 
transferred into cofactor-free solution. Afterwards the enzyme is precipitated by 
addition of an acidic solution and the enzyme-bound cofactor is liberated 103 50. The acid-
stable ThDP can be analyzed quantatively by 1H NMR spectroscopy after removal of the 
precipitated protein. While ThDP was found after acidic treatment of full length TKT no 
cofactor was detected in the deletion variant (Figure 20). Summarizing both, the near-
UV CD and 1H NMR spectroscopy experiments strongly indicate that TKTΔ38 is unable to 






3.1.5 Analysis of the oligomeric state of TKT and TKTΔ38 by analytical 
gelfiltration 
Another possible explanation for the absence of enzymatic activity in the deletion 
variant could be its incabability to form the catalytically active homodimer. To address 
this question analytical gel filtration experiments were performed with native TKT and 
TKTΔ38. 
Both proteins elute in a single peak, reflecting one dominant oligomeric state in each 
case (Figure 21). The difference in the retention time of the deletion variant is 
considerably affected, which results in a retention time not corresponding to a putative 
mass difference of 4 kDa as it was expected for the TKTΔ38. Native TKT shows a mass of 
135 kDa (theoretical Mr for the expected homodimer ~125 kDa). The observed mass of 
the deletion variant was with 70 kDa significantly lower indicating that TKTΔ38 exists 
mainly as monomer (theoretical Mr ~64 kDa). 
It can be concluded that the deleted 38 amino acids do not only impair cofactor binding 




























Figure 20: Cofactor binding analysis by near-UV CD and 1H NMR spectroscopy in full length TKT and the TKTΔ38 
deletion variant. (A) Near-UV spectra analysis of TKT and TKTΔ38 at a concentration of 2 mg/mL enzyme in glycyl 
Glycine buffer, pH 7.6 containing 500 mM NaCl. Noteworthy is the missing absorption at 320 nm for TKTΔ38. (B) 
1H NMR spectroscopic analysis of supernatant obtained after acid quench treatement of TKT and TKTΔ38. Shown is 
the downfield section of the NMR-spectrum (10-9.5 ppm). Within this range a signal is located at ~9.705 for TKT which 
can be assigned to the C2-H of the thiazolium portion of the ThDP cofactor. No corresponding signal was detected in 





3.2 Phosphoketolase of B. breve 
3.2.1 Expression and purification of wt XFPK and active site variants 
Wild-type XFPK and several active site variants (H64A, H97A, H142A, H320A and H553A) 
were expressed as C-terminal hexahistidine fusion proteins and purified stepwise by 
immobilized metal ion affinity chromatography (IMAC), ion exchange chromatography 
(IEX) and size exclusion chromatography (SEC) as previously described. For all of these 
variants a decrease or even loss of activity has been reported, highlighting the 
importance of the respective histidines for XFPK catalysis 80. 
 
Table 3: Kinetic parameters of active site variants of XFPK. 
Adapted from to Suzuki et al. (2010), (NA no activity). 
variant kcat (min
-1) KM app (F6P) KM app (Pi) Tm (K) 
wt 1540 ± 60 9.7 ± 0.3 1.2 ± 0.2 319.5 
H64A NA NA NA 327.5 
H97A NA NA NA 313.5 
H142A 12.2 ± 0.9 7.4 ± 0.6 1.7 ± 0.2 314.5 
H320A NA NA NA 319.9 
H553A NA NA NA 315.9 
Volume (mL)





































1: Thyroglobulin (bovine) 670 kDa
2: gamma-globuline (chicken) 158 kDa
3: Ovalbumin (chicken): 44 kDa
4: Myoglobulin (horse) 17 kDa
5: Cobalamin: 1.35 kDa
VE/VO
















Figure 21: Analytical gel filtration experiments of full-length TKT and TKTΔ38. (A) Elution profiles of a protein 
standard mixture, native TKT and TKTΔ38 (detected at 280 nm). (B) Plot of log molecular weight (MW) versus VE/V0 (VE 








All proteins could be purified to homogeneity in miligram scale (up to 200 mg from a 
20 g cell pellet). The His-tagged enzymes consist of 845 amino acids with a predicited 
molecular weight of 94.9 kDa. As it can be seen in Figure 22 the wild-type shows an 









3.2.2 Secondary structure and thermal stability of wt XFPK and variants  
To analyse the influence of amino acid exchanges in the active site on the 
thermodynamic stability, far-UV CD spectra were collected for all purified proteins. XFPK 
wt and the variants show a typical far-UV spectra as it can be expected for an (α/β)-
protein (see appendix). The only exception was the H142A variant, which precipitated 
during CD experiments (at 20 °C). This is an unexpected finding since kinetic 
characterization and crystallization of this variant was previously successful 80. 
Next, thermal unfolding was used to elucidate the stability of wt and variants. This 
process turned out to be irreversible for all characterized XFPK variants. As it can be 
seen in Figure 23 thermal unfolding followed a one phase transition, with the transition 
point located at ~319.5 K for the wild-type. All variants except H64A have a significantly 
decreased thermal stability (see appendix). Their transition points are in the range ~313-
328 K (see Table 3). Moreover, the wild-type seems to be stable under initial conditions 
(20 °C) whereas the variants already start to loose secondary structure elements under 
initial temperature conditions 293-303 K. The low stabilty of H142A observed in far-UV 
spectra experiments is underpinned by thermal unfolding results since it shows the 
lowest thermal stabilty. 
Figure 22: SDS-PAGE 







Figure 23: Far-UV spectra and thermal unfolding of wt XFPK. (A) Far-UV CD spectra of wild-type XFPK was recorded at 
a protein concentration of 0.1 mg/mL in 50 mM sodium phosphate buffer, pH 7.6 containing 2.5 mM MgCl2 and 
200 µM ThDP at 20 °C. (B) Thermal unfolding of XFPK was recorded at 222 nm in the same buffer as mentioned above. 
 
3.2.3 Analysis of enzymatic XFPK activty by discontinous acetyl phosphate 
detection 
Enzymatic activity of XFPK was analyzed by detecting the formation of the acetyl 
phosphate derived chromophoric complex hydroxamate as described earlier 104 80. The 
observed kinetic parameters for donor substrate F6P resembled those, that have 
previously been published (KM 24.6 ± 4.3 mM and kcat 18.6 ± 1.3 s
-1) (see Table 3) (Figure 
24) Determination of kinetic constants for the alternative donor substrate X5P could not 
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Figure 24: Dependence of the reaction rate of wt XFPK on the F6P concentration. Rate constants of substrate 
dependent acetyl phsophate formation were plotted according to the Michaelis-Menten equation. KM 24.6 ± 4.3 mM 
and kcat 18.6 s
-1 were decreased in comparison to previously published results. 
 
Given that the detection of acetyl phosphate by the hydroxamate assay mentioned 
above is a time consuming and error-prone method to determine kinetic parameters of 
XFPK, an isothermal titration calorimetry (ITC) based method was established. ITC is 
commonly used to quantitavely characterize interactions between biomacromolecules 
or other compounds 114 115. Moreover, ITC was adopted as a suitable tool for 
characterizing enzyme kinetics which is in particular interesting in cases where no 
suitable assay is available 116 106 117. In two different experimental setups the kinetic 
parameters KM and Vmax can be obtained. The first experiment is the successive titration 
of substrate into the ITC cell containing the enzyme. After each injection the steady-
state corresponding to the respective substrate concentration is established, resulting in 
a shift of the baseline that corresponds to the current reaction rate. This allows the 
detection of reaction rates at different substrate concentrations in one single titration 
experiment and thus the direct determination of KM 
106. To determine Vmax the amount 
of substrate that is consumed over time (ΔP in µM/sec) must be calculated from the 
total heat over time (ΔH in µcal/sec) (see appendix). Therefore, the molar enthalpy of 
the reaction ΔHapp is calculated from the heat, which is generated after injection and 
complete conversion of a distinct amount of substrate to the enzyme. 
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Figure 25: ITC detected heat release during wt XFPK driven F6P cleavage. (A) 525 nM XFPK in 20 mM HEPES (pH 7.2) 
containing 1 mM MgCl2, 50 mM Na2HPO4 and 200 µM ThDP were incubated for 2 min at 25 °C in the ITC cell until 
thermal equilibrium was established. Afterwards, successive injections of 5 times 0.5, 5 times 1 and 5 times 2 µL of 
350 mM F6P were performed every 150 seconds. (B) Integrated signals of the pseudo-first order reactions (red 
baselines in Figure A) plotted against the used substrate concentration. By this the KM can be obtained directly 
(6.3 mM). The catalytically inactive variant E479A served as negative control. 
 
As depicted in Figure 25 after initial thermal equilibration, injections of F6P to XFPK lead 
to a significant release of heat (decrease of instrumental power) demonstrating that the 
cleavage of F6P into acetyl phosphate and E4P is an exothermic reaction. To estimate 
the reaction rate, the difference between the initial baseline and the respective 
baselines after each single injection step were determined. A fit of the released power 
over time in dependence on the substrate concentration gives rise to KM which was 
determined by fitting the data according to Michaelis-Menten equation (KM 6.3 ± 
0.45 mM). This is in fair agreement with previously published data (9.7 mM) and proves 
the applicability of the ITC-based assay. 
To characterize all kinetic parameters of XFPK according to equations 4-7 (see appendix), 
the apparent enthalpy ΔHapp was determined. This was performed by titrating substrate 
with a final concentration of 3 mM to the enzyme (5.3 µM) and recording of complete 
turnover. After the baseline has returned to its origin another titration was performed to 
elucidate if the product inhibits the reaction. As depicted in Figure 26 after a first 
injection the substrate becomes totally consumed resulting in an over all heat release of 
~ 4360 cal/mol (for calculations see appendix). A second and third titration did not lead 
to a comparable amount of heat release which is presumably caused by product 
inhibition as it was previously reported for XPKs 81. To validate this assumption, single 
ITC Kinetik
0,05 mg/mL BbXFPKwt in 20mM HEPES pH 7,2 + 1 mM MgCl
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4360 cal/mol 1861-3174 cal/mol
injection experiments were performed with increasing amounts of F6P (0.3-30 mM). In 
theory the released heat per mole substrate should be independent of the used 
substrate concentration. While this assumption holds true for F6P concentrations up to 
3 mM (~4200-4400 kcal/mol) we observe significant deviations at higher concentrations 
(~1800-3200 kcal/ ol) (Figure 26). 
 
 
Figure 26: Determination of apparent enthalpy (∆Happ) by complete substrate conversion. (A) Injection of 1.3 µL of a 
350 mM F6P solution into the ITC cell (final concentration 3.11 mM) containing 5.3 µM XFPK in 20 mM HEPES (pH 7.2, 
1 mM MgCl2, 50 mM Na2HPO4 and 200 µM ThDP. F6P cleavage was monitored until the original baseline value was 
reached. A second and third titration of substrate gave not the same amount of heat release. (B) Injection of 1.3 µL of 
a 35 mM F6P solution into the ITC cell (final concentration 0.31 mM) containing 5.3 µM XFPK in 20 mM HEPES (pH 
7.2), 1 mM MgCl2, 50 mM Na2HPO4 and 200 µM ThDP. F6P cleavage was monitored until the original baseline value 
was reached. The integral of the thermogram corresponds to a heat release of 4124 cal/mol. (C) Injection of 1.3 µL of 
a 350 mM F6P solution into the ITC cell (final concentration 3.11 mM) containing 5.3 µM XFPK in 20 mM HEPES (pH 
7.2), 1 mM MgCl2, 50 mM Na2HPO4 and 200 µM ThDP. F6P cleavage was monitored until the original baseline value 
was reached The integral of the thermogram corresponds to a heat release of 4360 cal/mol. (D) Injection of 13 µL of a 
35 mM F6P solution into the ITC cell (final concentration 31 mM) containing 5.3 µM XFPK in 20 mM HEPES (pH 7.2, 1 
mM MgCl2, 50 mM Na2HPO4 and 200 µM ThDP. F6P cleavage was monitored for over 2 hours. The baseline did not 
return to its origin and integration of the thermogram values between 1861 and 3174 cal/mol depending on the end 





This restriction makes the ITC method not useful for a complete kinetic characterization 
of XFPK but a rough estimation of KM is still accessible (due to product inhibition KM is 
also decreased; therefore derived data have to be discussed with caution). 
ITC was applied to elucidate wether XFPK is able to convert the seven-carbon sugar 
phosphate S7P, an intermediate of the PPP (see section 1.2). The analysis of this titration 
experiment revealed that S7P is not converted by XFPK. Last the different oligomeric 
fractions of XFPK were analyzed for catalytic activity (Figure 27). It was reported that 
only the homohexameric fraction of XFPK shows significant activity 80. While tetramers 
and hexamers possess similar turnover rates and KM, we observe a ten-fold lower affinity 




As XFPK is inhibited by the product erythrose 4-phosphate the kinetic analysis was 
restricted to the estimation of KM. Moreover, this aspect has not been further 
investigated by use of the hydroxamate assay, due to its inconvenience. 
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Homotetramer (KM 3.8 ± 0.46 mM)
Homohexamer (KM 4.9 ± 0.45mM)
XFPK wt + S7P
Figure 27: ITC based analysis of potential alternative substrate usage (S7P) and validation of activity of the different 
oligomeric states of wt XFPK. (A) 525 nM XFPK in 20 mM HEPES (pH 7.2) containing 1 mM MgCl2, 50 mM Na2HPO4 
and 200 µM ThDP were incubated for 2 min at 25 °C in the ITC cell until thermal equilibrium was established. 
Afterwards 20 successive injections 2 µL of 311 mM F6P were performed every 120 seconds. B) 525 nM XFPK 
monomer, dimer and trimer in 20 mM HEPES (pH 7.2) containing 1 mM MgCl2, 50 mM Na2HPO4 and 200 µM ThDP 
were incubated for 120 seconds at 25 °C in the ITC cell until thermal equilibrium was established. Afterwards 5 




3.2.4 Analysis of protonic and tautomeric equilibria of enzyme-bound 
cofactor of XFPK by CD spectroscopy 
Since the active centers of TKT and XFPK share a high homology we expected to observe 
a similiar spectroscopic signature for the UV-CD experiment with XFPK as previously 
described (section 3.1.4). However, no negative signal around 320 nm could be detected 
in XFPK even after addition of up to 10 fold excess of ThDP and Mg2+ (Figure 28). On the 
other hand, two signals can be seen below 300 nm, one positive signal at 290-300 nm 
and a negative signal at 280-290 nm. These signals have previously been assigned to 
different tautomerization and ionization states of the ThDP-cofactor 48. The positive 
signal is supposed to reflect the so called 1’,4’-iminopyrimidine (IP) form of the cofactor 
whereas  the negative signal putatively represents the 4’-aminopyrimidinium (APH+) 
state although it was described to be located at 260-270 nm (Figure 7). XFPK shows such 
signals even in the abscence of ThDP in the buffer indicating that ThDP is tightly bound 























Col 2 vs Col 6 
Col 9 vs Col 14 
Col 16 vs Col 21 
Col 23 vs Col 28 
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XFPK (1mg/mL)
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Figure 28: Near-UV spectra analysis 
of wt XFPK at a concentration of 
1 mg/mL enzyme in Hepes (pH 7.2). 
The spectrum after adding 1 mM 
ThDP and 10 mM MgCl2 was 
truncated below 300 nm since the 
free ThDP cofactor shows a high 




3.2.5 pH dependence of the internal tautomeric euquilibrium of XFPK-
bound ThDP 
On the basis of CD spectra for enzyme-bound ThDP at different pH values the pKas of 
AP, APH+ and the IP form have previously been determined for different ThDP 
enzymes 49. Based on these experiments it was suggested that all postulated tautomeric 
states exist at the active site in ThDP-dependent enzymes under physiological 
conditions. However, their relative abundances significantly differed among the studied 
proteins. To get an insight of such equilibria in XFPK-bound ThDP, pH-titration 
experiments in the range of pH 6-9 where performed within the present work. At higher 
or lower pH values the wt as well as the variants denatured. 
  
Increasing the pH value of the buffer leads to depletion of the APH+ signal and an 
accumulation of the IP signal (Figure 29). This is an expected finding since the addition of 
hydroxyl ions should lead to deprotonation of the APH+ form. An AP derived signal is 
undetectable although the presence of this tautomer was expected under low pH 
conditions 49. 
Titration experiments performed with the active center histidine variants were not that 
conclusive (see appendix). Although a slight comparable tendency as described for the 
wild type could be detected, it seems that transferring the variants into cofactor-free 
CD titration
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Figure 29: Near-UV spectra analysis of 
wt XFPK at different pH values. 
Measurements were performed at a 
concentration of 1 mg/mL enzyme in 
MES/PIPES/TRIS buffer (20 mM, pH 6-9). 
All spectra are cored for volume changes. 
An increase of the pH-value leads to a 
decrease of the APH+ signal and an 
increase in the IP signal. The insert (top 
right) shows the difference spectra 
(spectrum at pH 6.02 minus spectrum at 
pH 9.02) reflecting the overall change in 




buffer leads to the formation of apo-enzyme and a loss of CD signal. This finding 
indicates the importance of each active site histidine for cofactorbinding. 
 
3.2.6 Analysis of covalent reaction intermediates in XFPK formed during 
F6P conversion by 1H NMR spectroscopy 
It is still questionable, whether the AcThDP intermediate is formed directly during XFPK 
mediated donor conversion, or if dehydration of the DhEThDP intermediate and 
nucleophillic attack of phosphate takes place in a concerted manner (see section 1.5.3). 
To address this question 1H NMR spectroscopy was performed. For that purpose the 
reaction was either carried out in presence of F6P alone, or with F6P and phosphate, the 
two native substrates of XFPK. 
In absence of phosphate two distinct NMR signals at 7.36 and 7.37 ppm can be detected, 
which are specific for the AcThDP intermediate as reported earlier (Figure 30) 82. 
Moreover, a multiplet signal centered at 6.39 ppm can be detected which was assigned 
unambigeously to the methylene bridge of the carbinolform of AcThDP. This species has 
a characteristic coupling constant of 16 Hz 82. Contrary, when XFPK was incubated with 
F6P and phosphate the only detectable signal at 7.31 ppm which is specific for 
DhThDP 103. Whether AcThDP is indeed an intermediate of this reaction or just an 
artificial “dead-end” product which is formed in absence of substrate phosphate could 
not be answered yet. NMR measurements of the variants could not be perforemd to a 
greater extent. Preliminary results for the histidines 64, 97 and 320 can be found in the 
appendix. The histidines 97 and 320 show no ThDP-signal, indicating the formation of 
apoenzyme while transferring the enzymes into cofactor-free buffer. The histidine 64 
variant shows characteristic signals for ThDP-intermediates, but they could not be 
allocated to a distinct species, since the ThDP seems to have lost its phosphate anchor 












BbXFPK wildtype (15 mg/mL) in HEPES-NaOH 20 mM pH 7.2







3.2.7 Analysis of intermediate formation in the course of XFPK mediated 
catalysis by stopped-flow UV/vis absorbance spectroscopy 
3.2.7.1 Kinetic analysis of XFPK-driven F6P conversion 
To resolve F6P conversion by XFPK in more detail we performed rapid mixing, single-
jump stopped-flow experiments with UV/vis detection. It was shown for E.coli TKT that 
F6P addition leads to a significant absorption spectrum with a maximum between 295-
305 nm and between 320-335 nm 113. It is supposed that these signals correspond to the 
IP (295-305 nm) and the AP (320-335 nm) state of the aminopyrimidine moiety of ThDP. 
First, stopped-flow experiments were performed with different F6P concentrations in 
the abscence of phosphate to visualize the spectral signature of intermediates in XFPK. 
We could not detect any absorbance signal below 400 nm in a Jasco spectrophotometer 
(data not shown) or in the stopped-flow device. Unexpectetly, a positive absorption 
signal centered at 420 nm could be detected (Figure 31). While such red-shifted 
absorbance signals have yet been detected in several ThDP-dependent enzymes 113 this 
is the first observation of such an intermediate derived signal in any XFPK. Diederichs 
Figure 30: Analysis of intermediate generation after wt XFPK driven conversion of F6P by 1H 
NMR spectroscopy. (A) Addition of F6P and phosphate leads to generation of DhThDP as 
detectable intermediate at 7.31 ppm. (B) Incubation of XFPK with F6P only leads to 
generation of AcThDP, whose signals can be detected at 7.36 and 7.37 ppm, respectively. 
Moreover, an AcThDP-specific multiplet centered at 6.4 ppm with a coupling constant of 




and Lüdtke clearly assigned the molecular origin of this signal in EcTKT using fast kinetics 
and NMR-spectroscopy. In EcTKT this red-shifted, broad signal is generated by the 
DhEThDP intermediate (personal communication Dr. Stefan Lüdtke). In our experiments 
the signal strength at 420 nm increases with increasing substrate concentrations. These 
results indicate that spectral signatures of the formed intermediate are not unique to 
TKT and can also be found in other ThDP-dependent enzymes. It is still questionable 
whether the detected signal corresponds indeed to DhThDP, or AcThDP but our NMR 
results suggest this species to be the latter. 
For the conversion of F6P and phosphate with transiently formed AcThDP no signal at 
420 nm could be detected suggesting that this intermediates’ longevity is too short to be 
resolved by our experimental setup. 
 
 
Both kinetic phases (formation and depletion) of the 420 nm signal were fitted according 
to a first order exponential equation (Figure 32). By fitting the obtained rate constants 
with a hyperbolic equation, kmax could be determined with 77 ± 11 s
-1 and Ksapp with 
44.6 ± 10 mM. 
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Figure 31: Stopped-flow absorbance spectra of F6P conversion by wt XFPK. (A) Photo diode array (PDA) spectra of 
XFPK in 20 mM HEPES (pH 7.2) containing 1 mM MgCl2 and 200 µM ThDP after addition of 2.5 mM F6P at 25 °C in a 
stopped-flow spectrometer with a pathlength of 10 mm. Inset: zoom into the region 300 to 500 nm. (B) Time resolved 
PDA spectra of XFPK in 20 mM Hepes (pH 7.2) containing 1 mM MgCl2 and 200 µM ThDP after addition of increasing 






While applying this experimental setup on the different histidine variants it seems that 
they are unable to generate this absorption pattern in presence or abscence of 
phosphate (see appendix). Only the H142A variant, which was reported to show slight 
catalytic activity, gives rise to a weak signal. Since the residues have been described as 
important for generation of the DhThDP or the AcThDP-intermediate it is most likely 
that the observed signal can be assigned to the enol-form of the latter. In this regard the 
depletion of the spectroscopic signal can be deduced to the slow tautomerization of the 
enolAcThDP followed by hydrolysis with water as previously described for AcThDP if no 
phosphate is present 83. 
 
3.2.7.2 Reaction of XFPK-bound ThDP-intermediate with phosphate 
In order to analyze the reactivity of the XFPK bound intermediate towards phosphate a 
double-jump stopped-flow experiment was performed. After initial mixing of XFPK and 
F6P, the putative enolAcThDP intermediate was generated. In the second mixing step 
the so formed enzyme bound species was mixed with phosphate and the reaction was 
monitored at 420 nm by UV/vis stopped-flow spectroscopy (Figure 33). Addition of 
phosphate causes a rapid signal/intermediate depletion within less then 50 ms at a 
concentration of 3 mM phosphate (red curve). All curves were fitted according to a first 
order single exponential equation. With increasing phosphate concentrations this 
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Figure 32: Time resolved PDA spectra of wt XFPK driven F6P conversion. (A) First phase of F6P conversion by XFPK 
in 20 mM HEPES (pH 7.2) containing 1 mM MgCl2 and 200 µM ThDP at 25 °C in a stopped-flow spectrometer with a 
pathlength of 10 mm. (B) Obtained rate constants for formation of the intermediate plotted against the different 
F6P concentrations giving rise to kmax with 77 ± 11 s




process accelerates and reaches a rate constant of > 400 s-1 for 25 mM phosphate (blue 
curve). The plotted rate constants do not follow a hyperbolic behaviour, and kmax is not 
reached at 25 mM F6P (~ 20 fold KM of F6P). 
 
 
3.2.8 1H NMR spectroscopic H/D exchange experiments to verify the 
presence of the enol form of AcThDP 
To clearly assign the chemical state of the intermediates that are formed during 
conversion of F6P by XFPK and to better understand their formation 1H NMR 
spectroscopical experiments were performed. In brief, when incubating XFPK with F6P, 
the enzyme converts this donor substrate and E4P will be released while an enzyme 
bound two carbon fragment (DhEThDP) remains bound to the active site. Dehydration 
by a yet unknown mechanism yields AcThDP. Our previous experiments implicated that 
this species dynamically change between ketoAcThDP and enolAcThDP. In case the 
reaction of XFPK and F6P will be carried out in heavy water the deuterium from the 
latter would be incorporated continuously into the methyl group of AcThDP yielding a 
mixture of deuterated species (-CH3, -CH2D, -CHD2 and -CD3). Given that AcThDP is 
depleted by non-enzymatically hydration and subsequent release of acetate this allows 
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Figure 33: Rapid mixing experiment of wt XFPK bound enolAcThDP with the second substrate phosphate. (A) 
Sequential stopped-flow experiment with XFPK (2.5 mg/ml) in 20 mM HEPES (pH 7.2) containing 1 mM MgCl2 and 
200 µM ThDP mixed with increasing F6P concentrations at 25 °C. Addition of phosphate was performed in a stopped-
flow spectrometer with a path-length of 10 mm and at a temperature of 25 °C. Spectra were fitted according to a 
single exponential equation first order giving rise to the respective rate constants. (B) Plotting of the first order rate 




for an analysis of this product by 1H NMR spectroscopy. Deuterated actetate is 
spectroscopically silent whereas acetate gives a strong signale at 1.93 ppm. 
 
 
As shown in Figure 34 a distinct signal for the methyl group of acetate can be detected 
after incubation of XFPK with F6P in the abscence of phosphate (1.92-1.93 ppm). 
Performing the same experiment in deuterium oxide, a small residual peak can be 
detected at the position of the former acetate signal. But moreover a multiplet is visible 
~0.015 ppm highfield shifted from the methyl-group signal. This multiplet can be 
assigned as incomplete deuterated acetate (-CHD2 and –CH2D whereas complete 
deuterated acetate is spectroscopically silent. The two peaks at ~2.5 and 2.6 ppm 
correspond to the methyl groups located at the thiazolium- and the aminopyrimidine 
ring of the cofactor. Those signals served as internal standard. These experiments 
demonstrate that enzyme bound AcThDP indeed changes between the keto and enol 
form when bound to the active site of XFPK. If this process might have an importance for 
the reactivity of the intermediate and for catalysis of XFPK will be discussed later. 
 
3.2.9  Interactions of glutamate 437 with the pyrimidinium ring of ThDP 
In order to identify the catalytic function of glutamate 437, which is located atop the 
aminopyrimidine ring of ThDP (see introduction), this residue was exchanged by 








Figure 34: 1H NMR spectroscopic 
analysis of produced acetate 
after wt XFPK driven conversion 
of F6P in absence of phosphate. 
Generated acetate can be clearly 
detected at 1.93 ppm in aquaeous 
solution (black graph). The same 
experiment peformed in 
deuterium oxide leads to almost 
full depletion of the signal, due to 
spectroscopically silent, 
incorporated deuterium (red 
graph). The residual multiplet at 
1.92-1.93 ppm can be assigned to 






The variant turned out to have a comparable stability and secondary structure as the 
wild-type (see thermal unfolding and far-UV CD data in the appendix). Interestingly, the 
variant showed no activity for formation of acetyl phosphate, as verified by the 
hydroxamate assay and ITC kinetics even at protein concentrations of up to 2 mg/mL 
(Figure 36). This underlines a pivotal function for glutamate 437 during catalysis, either 
by stabilizing the active center of XFPK, coordinating the cofactor or by direct acid/base 
or electrostatic catalysis. Besides the incapability of the E437 variant to form acetyl 
phosphate could be confirmed in UV/vis stopped flow measurements since no signal for 










Figure 35: Location of Glu 437 
atop the pyrimidinring of the 
ThDP cofactor. Besides, for 
orientation the activation Glu 






Figure 36: Catalytic activity of XFPK E437Q (A) Hydroxamate assay. 2 mg/mL XFPK E437Q in 25 mM MES pH 6.5, 
0.1 mM MgCl2 and 200 µM ThDP were preincubated with 80 mM Na2HPO4 and then mixed with F6P (shown are the 
progress curves for 0 and 80 mM). (B) 2.1 µM XFPK E437Q in 20 mM Hepes (pH 7.2) containing 1 mM MgCl2, 50 mM 
Na2HPO4 and 200 µM ThDP were incubated for 120 sec at 25 °C in the ITC cell until thermal equilibrium was 
established. Afterwards 4 successive injections of 4 times 0.5, 4 times 1 and 4 times 2 µL of 311 mM F6P were 
performed every 150 seconds. 
 
Near-UV pH titration experiments with XFPK E437Q revealed unique spectroscopic 
signatures (Figure 38). As outlined for the wild-type an increase of the pH leads to a 
decrease of the APH+ signal while the IP form of the cofactor accumulates. The variant 
shows already an IP specific signal at low pH values which only slightly increases at 
higher pH. Contrary, the APH+ signal shows the same spectroscopical behaviour as wt 
XFPK instead. It is reasonable to assume that the negative charge of glutamate 437 
ITC Kinetik
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Figure 37: Time resolved PDA 
spectra of XFPK E437 driven 
F6P conversion. First phase of 
F6P conversion by XFPK E437Q 
in 20 mM HEPES (pH 7.2) 
containing 1 mM MgCl2 and 
200 µM ThDP at 25 °C in a 
stopped-flow spectrometer 
with a pathlength of 10 mm. 
Besides a slow increase of the 
absoprtion, putatively caused 
by precipitation, no signal of 
the AcThDP could be detected 




influences the spectroscopic characteristics of the aminopyrimidine ring of ThDP. 
Especially the IP signal is obviously qenched at lower pH values. After mutagenesis 
against an uncharged glutamine this restriction does no longer occur and the IP signal 
can be detected at lower pH values already. Importantly, this is a macroscopic 
description of absorbance signals. The molecular origins of the alternate spectroscopic 
behavior after amino acid exchange in the active site of XFPK are most probably 
disturbed equlibria of IP, AP and APH+. 
 
3.2.10 Structure of XFPK E437Q 
In order to correlate our spectroscopical and functional results on the active site variant 
E473Q with structural information, we crystallized this protein and determined 
structures in the ground state as well as in complex with DHeThDP/AcThDP. 
While the resting state of XFPK E437Q could be determined at a resolution of 1.48 Å, the 
structure of XFPK E473Q in complex with ThDP-intermediates had a resolution of 1.6 Å 
(Statistics see appendix). For both structures, residues 5-806 could be traced relying on 
2Fo-Fc and FoFc electron density maps. The first 24 amino acids (containing the 
hexahistidine sequence) and the last 19 amino acids of the C-terminal domain could not 
be traced because of mixing electron density for these moieties of the structure. As 
described by Suzuki et al. the XFPK monomer consits of three α/β-fold domains, which 
have been assigned as the N-terminal PP-domain (5-378), the middle Pyr-domain (379-
611) and the C-terminal domain (612-806) (see introduction). Interestingly, only the 
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0 Figure 38: Near-UV spectra 
analysis of XFPK E437Q at a 
concentration of 1 mg/mL. 
Increase of the pH-value leads 
to a decrease of the APH
+
 
signal. The already at low pH 
values present IP signal does 
only slightly change. Insert 
shows the difference spectra 
(spectrum at pH 6.46- 
spectrum at pH 9.03) reflecting 





hexameric fractions of XFPK were able to crystallize which was also observable for this 
variant. As expected, both determined structures of XFPK shown here revealed that 
ThDP binds in its typical V-conformation to the active site, a characteristic previously 
described for all ThDP-dependent enzymes. Mutation of glutamate 437 has no effect on 
the position of the histidine residues, which are important for catalysis. In order to 
estimate the impact of the substitution of E437Q we superimposed the wt XFPK 
structure and inspected the close proximity of ThDP and residue 437. While no 
structural changes are observable for the cofactor as well as for active site residues, 
residues glutamine 437 and tyrosine 501 revealed an increased flexibility relative to the 





For these two residues diffuse and undefined difference electron density maps |Fo Fc | 
are observable, that is most likely explained by different, interconverting side chain 









Figure 39: Electron density 
maps of resting ThDP in 
the XFPK E437Q variant. 
2|Fo|-|Fc| omit map of 
the ThDP cofactor is 
shown. Missing electron 
density can be observed 
between the C2 and the S1 
of the thiazolium ring. 
Beside there seems to be a 
connection between the C2 
and the N4’ of the 
pyrimidinring (for 
discussion see text). 
Tyr 501 and Gln 437 show a 
high flexibility, reflected by 





for the second substrate phosphate. Interestingly, all soaking experiments of the variant 
with phosphate were so far not successful, strongly indicating that tyrosine 501 is indeed 
essential for phosphate binding and that increased flexibility of this residues impaires 
this process. This conclusion is in line with the unability of this variant to generate acetyl 
phosphate (see section 3.2.9). For glutamine 437 two alternate conformations could be 
traced. Another interesting observation is missing electron density for the cofactor in 
2|Fo|-|Fc| simulated annealing omit map between the C2 and the S1 of the thiazolium 
ring and a residual electron density between the C2 and the N4’ of the aminopyrimidine 
ring. Suzuki et al. reported a comparable phenomenon for the structure of XFPK H64A. 
They postulated ThDP to exist in a tricyclic state (dihydrothiachromine; structure see 
appendix) 118. Attempts to model this trycyclic form into our obeserved electron density 
showed no good accordance (see appendix). Even a ThDP-modell with a broken covalent 
bond between the C2 and the S1 did not fit into our observed data (see appendix). 
Besides, the weak electron density for the reactive C2 atom might indicate the presence 
of a ThDP carbene. Carbenes are highly reactive species and possess an elctron sextet in 
contrast to an octet in protonated ThDP 113. 
 
In order to accumulate the intermediates, crystals of XFPK E437Q were soaked for 
several minutes with 54 mM F6P. Strong, additional electron density at the C2 of the 
thiazolium ring could be observed. Assuming that under the chosen soaking condition 
several covalent intermediates will be generated and that the stability of each 
intermediates might be different in the characterized variant we refined our structures 
with both post-cleavage intermediates (DHeThDP and AcTHDP). Analysis of the 
difference electron density maps after refinements, clearly revaled the accumulation of 




However, we observe weak residual electron density atop the sp2 hybridised C2α-atom 
indicated the presence of a small fraction DhThDP intermediate. This is in accordance to 
previously published data 80. These findings underpin, that glutamate 437 has impact on 
the coordination of the cofactor but directly influences phosphate binding in 
collaboration with tyrosine 501. NMR studies on the intermediate distribution of this 
variant could so far not be performed 
 
3.3 Transketolase-like proteins 1 and 2 
3.3.1 Recombinant expression of TKTL1 and 2 in E. coli 
In order to functionally characterise TKTL1 and 2 in detail, high amounts of purified 
enzyme were needed. For that purpose two artificial gene-constructs coding for TKTL1 
and 2 were designed (Uni Prot identifier: P51854 (TKTL1); Q9H0I9 (TKTL2)) and 
subsequently cloned into the pET-SUMO expression vector (provided by Dr. Kathrin 
Schröder-Tittmann [Department for Bioanalytics, Georg-August-University Göttingen]). 
In previous experiments using different E. coli strains (BL 21 star, Arctic express, SoluBL 
21 SG 1309, JM 109, RIL and C600, personal communication Dr. Stefan Lüdtke), 
recombinant TKTL1 and 2 expressions resulted in formation of insoluble proteins. 
Solubility of the desired proteins could not be increased by lowering the temperature 
during expression, use of autoinduction media, adding a lower amount of IPTG or 
addition of up to 2 % ethanol (v/v) to induce chaperone formation. Cloning of TKTL1 and 






Figure 40: Electron density maps of 
AcThDP in the XFPK E437Q variant. 
2|Fo|-|Fc| omit map of the AcThDP 




different tags (GST and Strep) had no effect on protein solubility too (data not shown). 
This is a common phenomenon when expressing human proteins in E.coli since 
posttranslational modifications, needed for proper protein-folding, can not be 
performed. To overcome this problem it was intended to establish a eucaryotic cell 
based expression system. 
 
3.3.2 Recombinant expression of TKTL1 and 2 by usage of the Bac-to-
bac™ expression system 
To overcome the problem of insoluble TKTL1 and 2 by use of a procaryotic expression 
system, the Bac-to-bac™ insect cell expression system was used. Therefore genes 
encoding for TKTL1 and 2 were cloned into a baculovirus genome. Baculovirus-DNA was 
transfected into three different insect cell cell-lines (Sf9 and Sf21 derived from 
Spodoptera frugiperda as well as Hi5 cells derived from Trichoplusia ni). After virus 
generation in transfected cells, virus particles were used to inoculate expression cultures 
of the named cell lines and induce TKTL1 and 2 expressions. The Hi5 cell-line turned out 
to be the most suitable one, due to the strongest expression of the desired proteins and 
was therefore used for protein expression (Figure 41). However, although expression of 
TKTL1 and 2 was successful in this expression system, both proteins remain in the 
unsoluble fraction after cell lysis and centrifugation. Even after a first chromatographic 
purification step by IMAC (TKTL1 and 2 are fused to a hexa-histidine sequence) only 

































3.3.3 Fed batch expression of TKTL1 and 2 
Although TKTL1 and 2 turned out to be located mainly in the unsoluble fraction after 
E.coli based expression in baffled flasks, slight amounts of protein could be located in 
the supernatant fraction (about 0.2 mg from a 20 g cell pellet). To increase the total cell 
mass, and by this to generate a higher amount of soluble enzyme in-total, a fed batch 
based expression was performed in analogy to the expression described for native 
human TKT. For that purpose the pETSUMO TKTL1 and 2 constructs were transformed in 
E.coli BL21 Star cells. Fermentation was performed in a Biostat C Biofermenter 
(Sartorius, Göttingen) as described in Section 2.8.14. Harvested cells were lysed and 
TKTL1 and 2 were purified using affinity chromatography. In comparison to baffled flasks 
expression, lysis of a higher amount of cell material (100 g cells) led to significantly 
detectable TKTL1 and 2 (Figure 42) in SDS-PAGE analysis after a first IMAC purification 
step. The amount of purified protein of interest was in the range of several milligrams 
(up to 2 mg per 40 g cell pellet). As can be seen in Figure 42 a double band appeared in 
the area of the expected mass of TKTL1 and 2. ESI-MS experiments of trypsin-digested 
protein samples (peformed by Dr. Oliver Valerius [Departement for Molecular 
Microbiology and Genetic, Georg-August-University Göttingen]) revealed that the upper 
band corresponds indeed to TKTL1 or 2 in SDS PAGE analysis. The lower one was shown 
to be DnaK, a chaperone of E.coli, whose co-purification was described as a severe 
problem during recombinant expression in E. coli 119. DnaK was removed by incubating 
Figure 41: SDS-PAGE analysis of TKTL1 and 2 expression in Hi 5 cells. (A) Cells were lysed after 24 h and total 
cell lysate was analyzed for TKTL1 and 2 expression 1: TKTL1, 2: TKTL2. (B) Western blot analysis of 
recombinantly expressed TKTL1 and 2 after a first chromatographic purification step. Only trace amounts of 
soluble protein were obtained in both cases (<0.1 mg). The main potion of the desired proteins remained in 





the samples with ATP and MgCl2 (up to 10 mM). However removal of the chaperone 
severely affects the solubility of TKTL1 leading to precipitation of the mayor fraction of 
the protein with amounts of below 0.2 mg of soluble protein.  
 
 
3.3.4 A chaperone TKTL1 and 2 fusion construct for recombinant 
expression 
Since contamination of TKTL1 and 2 with the E.coli derived chaperone DnaK turned out 
to have a positive effect on the solubility of the desired proteins, a different expression 
strategy was applied. For that purpose TKTL1 and 2 were c-terminally fused to the E.coli 
trigger-factor chaperone, to increase solubility and facilitate purification. For further 
processing the trigger factor can be removed by protease digestion with i.e. thrombin or 
the HRV3C-protease. The trigger factor belongs to the best-characterised chaperones 
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Figure 43: SDS-PAGE analysis of purified TKTL1 and 
2. (1) TFTKTL1, (2) TFTKTL2,  TKTL1 after thrombin 






Figure 42: SDS-PAGE analysis of purified fed-
batch derived SUMO-TKTL 1. During 
purification of SUMO-TKTL1 an E.coli derived 
chaperone (DNAK) becomes co-purified (1). 
The chaperone can be removed by incubation 
with ATP (2). This however leads to immediate 




Generation of the construct, transformation, expression and purification were 
performed as outlined in the material and methods section. After a first IMAC 
purification step high amounts of the desired proteins could be obtained. After an 
overnight digestion with the HRV3C-protease a SEC step was performed as well as 
another IMAC to remove undigested proteins and the proteases. Purification of TKTL1 
and 2 was succesfull (Figure 43). The amount of purified protein was in the range ouf 
several milligrams (up to 60 mg from a 20 g cell pellet) and the proteins turned out to be 
stable under the used conditions. While expected molecular weights are 67 kDa for 
TKTL1 and 69 kDa for TKTL2 it can clearly be seen that the mass of both proteins lies in 
the range of approximately 60 kDa, independent of whether HRV 3C protease or 
thrombin were used. This contradicts an unspecific proteolytic cleavage of both proteins 
by the protease since the cleavage sites clearly differ and the sequences of TKTL1 and 2 
contain no such sequence besides the one between protein and trigger-factor. An SDS 
PAGE analysis of either thrombin or HRV3C digested TFTKTL1 and 2 can be found in the 
appendix. Differences in the apparent molecular weight of TKTL1 in-vivo have been 
reported earlier by other workgroups 75 but similiar behaviour for TKTL2 has never been 
reported 
 
3.3.5 Secondary structure and thermal stability of native TKTL1 and TKTL2 
To compare structural differences between TKTL1, TKTL2 and native human TKT far-UV 
CD was applied. 
The CD spectrum for the trigger-factor TKTL1 and 2 fusion proteins (TFTKTL1 and 2) are 
comparable to a typical (α/β)-protein with two negative bands at 208 nm and 220 nm, 
and a positive signal at 195 nm. CD spectra of TKTL1 and 2, whose trigger-factor fusion 
protein was cleaved off by thrombin digestion, showed similiar absorption spectra to the 
respective trigger-factor fusion constructs. The two negative signals at 208 nm and 
220 nm are clearly visible, as well as a positive signal at 195, reflecting a typical (α/β)-
protein. CDNN software calculations are summarized in Table 4. These values are in fair 
aggreement with the secondary structural content of TKT derived from crystallographic 




code: 3MOS) 120 except for the α-helical content of TKTL1 which had significantly 
dropped down. 
 
Table 4: CDNN analysis of secondary structure contents of TFTKTL1, TFTKT2, 
TKTL1 and TKTL2. 
 α-helical content (%) β-sheet content (%) 
TFTKTL1 37 16 
TFTKT2 29 18 
TKTL1 23 19 
TKTL2 31 17 
 
The CD spectra of the different constructs are due to the strong absorbance of the used 
high salt buffer limited to wavelengths above 200 nm. Despite this restriction the overall 
spectra of TFTKTL1 and 2 look comparable to those of a typical fold of a (α/β)-protein. 
Noteworthy is a smaller absorption at 222 nm corresponding to a loss of a α-helical 
based signal (Figure 44). 
Next the stability of the proteins was analyzed by thermal unfolding which turned out to 
be an irreversible process in all cases. The unfolding process of TFTKTL1 and 2 turned out 
to follow a one phase transition with a transition point at 325 and 323 K. This differs 
significantly from native TKT with two transition points under high salt conditions at 326 
K and 337 K as well as the deletion variant with 317 K. Removing the trigger factor fusion 









3.3.6 Enzymatic characterisation of TKTL1 and 2 
To verify if TKTL1 and 2 possess a catalytic transketolase function a coupled enzymatic 
assay was performed. Furthermore X5P and CoA were used since it was reported that 
TKTL1 cleaves X5P into G3P and a C2-fragment of unknown chemical structure identity 
which was hypothesized to be further converted to acetyl-CoA. In both assays cleavage 
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Figure 44: Far-UV spectra and thermal unfolding of TFTKTL1 and 2 as well as the trigger-factor released TKTL1 and 2 
constructs. (A) Far-UV CD spectra of TFTKTL1 and 2 were recorded at a protein concentration of 0.1 mg/mL in 50 mM 
sodium phosphate buffer, pH 7.6 containing 500 mM NaCl, 2.5 mM MgCl2 and 200 µM ThDP at 20 °C. (B) Thermal 
unfolding of TFTKTL1 and 2 recorded at 222 nm in the same buffer as mentioned for the far-UV CD measurements. (C) 
Far-UV CD spectra of TKTL1 and 2 were recorded at a protein concentration of 0.1 mg/mL in 50 mM sodium 
phosphate buffer, pH 7.6 containing 500 mM NaCl, 2.5 mM MgCl2 and 200 µM ThDP at 20 °C. (D) Thermal unfolding of 







As control native TKT was used. No enzymatic activity could be detected for TKTL1 and 2 
even after an increase of the used enzyme-concentration of up to 2 mg/mL (Figure 45). 
While performing the same experiment with the undigested TFTKTL1 and 2 constructs 
an unspecific oxidation of NADH could be observed, even in the abscence of the 
substrates X5P, R5P and CoA. The observed unspecific NADH-oxidation was presumably 
caused by co-purified proteins which were present in the used TFTKTL1 and 2 fractions 
(see appendix). 
 
3.3.7 Product analysis of a putative TKTL1 and 2 activity by mass 
spectrometry 
To further investigate whether the purified TKTL1 and 2 proteins show enzymatic 
activity, nano-electrospray tandem mass spectrometry experiments were performed by 
courtesy of Dr. Cornelia Herrfurth (Department for Plant Biochemistry, Georg-August-
University Göttingen). After quenching the reaction, the protein was removed by 
filtration and the supernatant analyzed as described in section 2.8.29. As depicted below 
neither TKTL1 or TKTL2 showed detectable production of G3P, S7P or acetyl-CoA. 
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TKTL1 and 2 (2 mg/mL)
Figure 45: Steady-state kinetic analysis 
of enzymatic activity of TKTL1 and 
2.Conversion of substrates X5P and R5P 
into S7P and G3P by a TKT-like mediated 
enzymatic activity were coupled to the 
consumption of NADH (340 nm) at 30 °C. 
Moreover the putative cleavage of X5P 
and transfer of the residual C2-fragment 



























































































































































































































Figure 46: Total scan and ms/ms 
spectra of the putatively used 
substrates and generated products of a 
TKTL1 and 2 mediated enzymatic 
reaction. (A) Total scan and ms/ms 
spectra of the used substrates X5P, R5P 
and Coenzyme A (top). CID derived 
spectra gave rise to the expected 
substrate-signals (229.1 for X5P and 
R5P (middle); 766.4 for CoA (bottom). 
(B) Total scan and ms/ms spectra of the 
expected products G3P, S7P and acetyl-
CoA (top). CID derived spectra gave rise 
to the expected product-signals (169.2 
for G3P; 289.3 for S7P (middle); 808.5 
for acetyl-CoA (bottom). 
Figure 47: Total scan and ms/ms 
spectra of the putatively used 
substrates and generated products of 
an TFTKTL1 and 2 mediated enzymatic 
reaction. (A) Total scan and ms/ms 
spectra of the used substrates X5P, R5P 
and Coenzyme A (top). CID derived 
spectra gave rise to the expected 
substrate-signals (229.1 for X5P and 
R5P (middle); 766.4 for CoA (bottom)). 
(B) Total scan and ms/ms spectra of the 
expected products G3P, S7P and acetyl-
CoA (top). CID derived spectra gave rise 
to the expected product-signals (169.2 
for G3P; 289.3 for S7P (middle); 808.5 





Based on these results it seems unlikely that TKTL1 and 2 perform a transketolase-like 
reaction. Moreover, the previously reported cleavage of X5P into G3P and putative 
formation of acetyl-CoA could not be reproduced. 
 
3.3.8 Analysis of cofactor binding by near UV CD spectroscopy 
Binding of the ThDP cofactor in TFTKTL1 and 2 as well as TKTL1 and 2 was investigated in 
analogy to the previously described deletion variant experiments (section 3.1.4). No TKT 
specific negative CD signal could be detected in the TFTKTL1 as well as in the TKTL1 and 
2 constructs under any tested condition (up to 10 mM ThDP and Ca2+) (Figure 49). This 
outcome either corresponds to an absence of cofactor in the mentioned proteins or a 




















































































































Figure 48: Total scan and ms/ms 
spectra of the putatively used 
substrates and generated products 
of an TFTKTL1 and 2 mediated 
enzymatic reaction. (A) Total scan 
and ms/ms spectra of the used 
substrates X5P, R5P and CoA (top). 
CID derived spectra gave rise to the 
expected substrate-signals (229.1 for 
X5P and R5P (middle); 766.4 for CoA 
(bottom)). (B) Total scan and ms/ms 
spectra of the expected products 
G3P, S7P and acetyl-CoA (top). CID 
derived spectra gave rise to the 
expected product-signals (169.2 for 





NMR studies to verify ThDP binding in TKTL1 and 2 could so far not be performed. 
 
Wavelength (nm)


































Figure 49: Cofactor binding analysis by near-UV CD. (A) Near-UV spectra analysis of TFTKTL1 and 2 at a concentration 
of 2 mg/mL protein in glycyl glycine buffer, pH 7.6 containing 500 mM NaCl. (B) Near-UV spectra analysis of TKTL1 and 
2 at a concentration of 2 mg/mL enzyme in glycyl glycine buffer, pH 7.6 containing 500 mM NaCl. Noteworthy is the 





4.1 The ∆38 deletion variant of human transketolase as model for TKTL1 
TKTL1 is an isoform of human TKT that has been described to act as a putative key-
player in establishing of an altered tumor cell metabolism by a gain of function role. It is 
supposed to drive a tumor cells’ metabolism towards a glycolytic phenotype, despite 
sufficient oxygen concentrations for respiration 53. By quantitative real-time PCR an 
increased expression of TKTL1 was detected in severral cancers 121 63. Besides elevated 
mRNA levels, TKTL1 was detected by immunostaining by use of a monoclonal antibody 
specific against TKTL1 53. Furthermore raised expression levels of TKTL1 have been 
assigned as a negative factor in terms of metastasis-formation and over-all survival of 
patients suffering from cancer 121 122 63. 
TKTL1 was supposed to convert the native TKT substrate X5P into G3P and a two-carbon 
unit of unknown identity, which was suggested to be acetyl-CoA. This lyase-reaction was 
hypothesized to be analogue to the reaction of XFPK of lactic acid bacteria that produces 
acetyl phosphate as product 53. In this regard a very low TKT activity of TKTL1 was 
presented to underpin the proposed enzymatic activity. Specific activities of this TKTL1 
reaction were not shown by the authors and substrate consumption was measured over 
24 hours. A native human TKT mediated reaction would convert the substrate within a 
few minutes under the described conditions 50. 
Facing these inconsistent data a deletion variant of native human TKT was generated by 
an overlap extension PCR method yielding an artificial TKTL1-construct (TKT∆38). This 
pseudo-TKTL1 lacks 38 amino acids in the N-terminus (residue 76-113) which have been 
described as the main difference between TKT and TKTL1 (Figure 9). After successful 
expression of this construct in E.coli the resulting protein could be purified to 
homogeneity, yielding several mg of protein. Purified TKT∆38 was biochemically 
characterized and compared to full-length TKT. Native TKT was previously characterized 
after E.coli based recombinant expression as an active enzyme, suggesting that no post-
translational modifications are necesary for enzymatic activity. In contrast the data 
obtained in the present work show that deletion of the 38 amino acids in full-length TKT 
leads to enzymatically inactive protein, underpinning the importance of this sequence 














studies, as well as a generated deletion variant lacking the same 38 amino acids as 
presented in this work 123 124. The incapability of cofactor binding in the deletion variant, 
analysed by near-UV CD and 1H NMR spectroscopy, can be considered as origin of this 
lack of enzymatic activity (Figure 20). Although TKTΔ38 is able to fold with a proper 
secondary structure, its thermal stability was severely reduced in comparison to full-
length TKT as distinguished by far-UV CD (Figure 18). Attempts to crystallize the deletion 
variant failed so far, despite extensive trials with conditions under which the native TKT 
crystallized reproducible 50. This restriction eliminated a further characterization of this 
variant by means of X-ray crystallography. Moreover the deletion affects formation of 
the homodimer, suggesting a role of the deleted helix-turn-helix motif the interaction of 
the respective monomers as shown by analytical gelfiltration (Figure 21). The consensus 
of TKTL1 and the deletion variant suggest the latter to be a good model, leading us to 
the assumption that TKTL1 does not possess an enzymatic activity relying on the ThDP 
cofactor. Therefore our results challenge the model of a proposed enzymatic role in 
tumor cell metabolism. However our data cannot rule out if a putative enzymatic activity 





Figure 50: Structure of the 
active site of human TKT 
highlighting the 38 amino 
acids missing in the deletion 
variant. Subunits of TKT are 
shown in green (subunit A) and 
orange (subunit B) with bound 
ThDP (yellow sticks) and Ca2+ 
(cyan). The deleted amino 
acids 76 to 113 of subunit A 
are shown in magenta. The 
two His 77 and 113, which are 
important for cofactor binding 





4.2 Elucidation of the catalytic mechanism of XFPK of B. breve 
4.2.1 Purification and kinetic analysis of wt XFPK and active site variants 
XFPK of B.breve was successfully purified according to a previously published protocol 79. 
The wild type enzyme as well as the variants H64A, H97A, H142A, H320A and H553A 
turned out to be stable under the choosen conditions. The only exception was the 
H142A variant which was prone to denaturation. All variants showed a lower thermal 
stability in comparison to the wild type. This was most likely caused by improper 
cofactor binding, whose contribution to the stability of the enzyme seems indispensable. 
Determining the kinetic parameters of wt XFPK by the discontinuous hydroxamat assay 
revealed a 2.5 fold elevated KM (24.6 ± 4.3 mM) and 30 % lowered lowered kcat of 18.6 s
-1 
± 1.3 in comparison to previously published data (Figure 24) 80. The origin of this 
discrepancy is so far unknown but it is most likely caused by the used error-prone assay 
or the mentioned product inhibition by E4P. Previously published KM values for F6P of a 
phosphoketolase form Lactobacillus plantarum were denoted with 24 ± 4 mM which is 
in a fairer agreement with our data 81. Applying an ITC based method for determining 
kinetic parameters failed probably due to the mentioned product inhibition by E4P, 
which has been studied earlier 81. According to Yevenes and Frey the three irreversible 
steps of XFPK mediated catalysis, dehydration of DhEThDP, tautomerization of the 
enolAcThDP to ketoAcThDP and phosphorolysis of the ketoAcThDP are the cause for 
product inhibition by E4P. They describe the way of inhibition as an uncompetitive way 
of action by E4P with respect to phosphate. It was proposed that this can be explained 
by Cleland’s rules since E4P and phosphate bind to different enzyme forms 125. Based on 
this, the only accessible data for our enzyme were the KM values for F6P (6.3 ± 0.45 mM) 
which are more comparable to the already published data on XFPK of B.breve. These 
data have to be considered with caution since lowering Vmax by product inhibition affects 









4.2.2 Protonic and tautomeric equilibria of XFPK and active site variants 
Since TKT and XFPK share a high degree of homology in the quarternary structure, which 
is expressed by a nearly equal active center composition, a similar spectroscopic 
behavior was expected in near-UV CD based measurements. As it was previously 
described 100 101 126. TKTs show a negative CD-absorption centered at 320 nm. Nemeria 
et al. assigned this band to be the AP form of the ThDP cofactor (Figure 51) 49. 
 
Figure 51: Tautomeric and ionization equilibria of ThDP in the resting state of ThDP-dependent enzymes. Adapted 
from Nemeria et al. (2007) 
 
For XFPK such a signal could not be detected (Figure 28). The reason for this finding is so 
far unknown since the signals for the putatively APH+ and IP form can be detected (this 
point will be discussed later). Besides, it seems that generation of this AP-signal is not 
caused by the same set of factors in different ThDP dependent enzymes. Nemeria et al. 
could show that formation of the AP derived signal depends on formation of the 
Michaelis-complex in the E1 component of the yeast and E.coli pyruvate dehydrogenase. 
However in TKT this signal can already be detected prior substrate addition, indicating 
that a general mechanism of AP signal generation by Michaelis-complex formation might 
not exist in this enzyme. Moreover it was shown by Asztalos et al. that the generation of 
the AP signal seems to depend on the presence of the N4’ amino group of the 
aminopyrimidine moiety of the cofactor 127. While adding F6P to XFPK a change in the 




leads to a strong ellipticity signal in the wavelength range below 320 nm overlapping 
with the tautomer signals of the ThDP cofactor (see appendix). It should be noted that 
substrates and amino acid residues as well as smaller molecules (i.e. Cl2-) present in the 
buffer systems used, can influence the spectoscopic behaviour of the generated near-UV 
CD signals 97. 
As mentioned above although no AP signal could be detected, a negative signal centered 
at 280 nm and a positive signal centered at 295 nm could be detected for XFPK (Figure 
28). The positive signal has previously been assigned to the IP form of the cofactor 49. In 
case of the negative signal we assume it to be the APH+ for of ThDP since it disappears 
while increasing the pH of the corresponding buffer (discussed below). Visualization of 
CD signals below 300 nm is not unambiguous, since proteins show a high signal in this 
wavelength range that are caused by aromatic amino acid side chains. Moreover the 
ThDP cofactor gives also rise to a strong CD signal centered at wavelengths below 
300 nm (see appendix), due to its strong absorption. 
To further assign the generated CD signals pH-titration experiments with wt XFPK and 
different active site variants have been performed (Figure 29). Titration experiments 
have already been described for other ThDP dependent enzymes like benzaldehyde 
lyase, benzoylformate decarboxylase, pyruvate oxidase and the E1 component of the 
pyruvate dehydrogenase complex 49. Using titration experiments the putative IP and 
APH+ signals could be confirmed for the wild type enzyme. The putative signal of the 
protonated APH+ form diminishes with increasing hydroxydion concentrations whereas 
the IP signal increases. Besides the signal for the AP form could not be visualized, 
although this was expected for higher pH values since it depicts the deprotonated form 
of APH+ as it was already reported for pyruvate decarboxylase 128. According to Jordan et 
al. ThDP dependent catalysis requires interplay of the different neutral and charged 
cofactor states but due to the given enzyme environment it is possible that in some 
cases not all signals can be detected. In case of the active center histidine residues the 
signal strengths of the recorded spectra were too low to make a qualitative assumption 
on the chemical state distribution of the cofactor. It seems that the affinity for ThDP is 
lowered and transferring the variants into cofactor free buffer (a prerequisite for near-




apo-enzyme formation. A fluorescence based analysis to determine KA values for ThDP 
for the wild type XFPK and the different variants could not be performed, since all so far 
applied protocols to generate XFPK apo-enzyme led to precipitation of the enzyme (data 
not shown). 
 
4.2.3 UV/vis stopped flow based analysis of enzyme-bound ThDP-
intermediate formation 
In order to gather more insights into the reaction mechanism of XFPK, UV/vis 
experiments, employing a stopped-flow instrument have been performed. Stopped-flow 
has been described as suitable tool for analyzing very fast microscopic steps of ThDP-
intermediate formation in TKTs 113 127 129. In TKTs signals for different tautomeric states 
at the aminopyrimidine ring after F6P-adduct formation have been described for the AP-
form (320-335 nm) and the IP-form (295-305 nm) 113. Performing UV/vis based 
approaches to elucidate the catalytic way of action of XFPK revealed an unexpected 
result after F6P addition. As described within stopped-flow UV/vis experiments, a 
prominent absorption signal in the wavelength range of ~420 nm can be detected in the 
absence of the second substrate phosphate (Figure 31). In case of E.coli TKT such a 
spectroscopic behaviour has been assigned to the formation of an enolat-species of the 






Figure 52: Chemical structure of DhThDP including tautomeric states of the enolat-enamin in E.coli TKT. The base 
being responsible for the putative enolate-enamine formation is so far unknown (either the IP form of the cofactor or 
an amino acid residue of the active center. In XFPK formation of such a species seems unlikely since it would hamper 
water elimination at the C3α. Figure adapted and modified from Meyer et al. (2012) 
 
In XFPK such a species seems rather unlikely since formation of an enolate would 
hamper protonation at the OH-group at the C3α to induce water elimination (see 
introduction). The close vicinity of the negative charges at the C3α would repel electron 
rearrangement after water elimination. 
Although it was still questionable to which chemical species this signal could be assigned 
(F6P-ThDP adduct, DhThDP, enolAcThDP or ketoAcThP) we suggest this signal represents 
the enolAcThP intermediate by several indications: 
1) The intermediate detected in 1H NMR spectroscopic analysis revealed accumulation of 
the AcThDP adduct in abscence of phosphate (discussed below). 
2) Analysis of the histidine residues of the active center by UV/vis showed only in the 
case of the H142A variant formation of this signal (see appendix). These residues have 
been described as important for either DhThDP-formation or enolAcThDP-formation. 
This means that all catalytic steps that depend on these histidine residues are upstream 
from the enolAcThDP in the catalytic cycle of XFPK (Figure 53). Analysis of the variants 





corresponds to the F6P-ThDP adduct or the DhThDP-intermediate where the respective 
catalytic step is blocked. 
 
 
Figure 53: Catalytic steps mediated by the conserved active site His residues in XFPK. His 64 and 320 are 
hypothesized to be responsible for the first catalytic step, protonation of the ThDP-adduct followed by release of the 
first product. His 97, His 142 and His 553 are supposed to catalyze interconversion of the second intermediate DhThDP 
into enolAcThDP. 
 
3) A similar spectroscopic behavior was described for the ThDP-dependent enzyme N2-
(2-carboxyethyl) arginine synthase (CEAS). This enzyme ligates the substrates G3P and 
arginine and is thus responsible for the first step of β-lactam antibiotic synthesis 131. 
During catalysis an acryloyl-ThDP intermediate is generated showing a comparable 
absorption at ~410 nm in UV/vis analysis. By using synthesized thiazolium analogues the 
authors could show that the resulting absorption is caused by the conjugated double 
bond system of the thiazolium and the terminal acryloyl-group. 
4) Crystallization attempts performed by Suzuki et al. showed difficulties in isolating the 




below). The authors explain that the DhThDP is transiently formed during catalysis and 
therefore hard to isolate 80. 
 
If we assign the spectroscopically detectable species to the enolAcThDP it is astonishing 
that the absorption shows its maximum in a wavelength range of 420 nm. One would 
expect the enol of such a small ketone to have an absorption maximum at the range of 
about 280 nm 82. It seems likely that the π-electrons of the putatively enolAcThDP are 
delocalized by interacting with the π-electrons of the thiazoliumring. This was explained 
for free AcThDP earlier, shifting the absorption spectra to ~310 nm 82. In our case there 
might be some additional interference with the aminopyrimidine ring of the cofactor. As 
described before, the two aromatic ring systems of ThDP seem to interact by a charge-
transfer mechanism leading to the red-shifted absorption signal 132. In case of enzyme 
bound ThDP such a mechanism occurs due to the V-orientation of the cofactor (in 
solution this conformation is thermodynamically not favored, hampering the described 
interaction) (Figure 54). This possible charge-transfer “communication” could explain 
the red-shifted absorption spectra of the detected enolAcThDP. 
 
 
Figure 54: Possible charge-transfer interaction of the aminopyrimidine- and the thiazolium ring of ThDP. 
 
4.2.4 UV/vis stopped-flow based kinetic analysis of phosphate catalyzed 
enzyme bound ThDP-intermediate conversion 
Analyzing the reaction of enzyme-bound enolAcThDP with the second substrate 
phosphate was performed by UV/vis sequential stopped-flow (Figure 33). After mixing 
XFPK with F6P, the intermediate was formed and its reaction with the second substrate 
phosphate was analyzed. Addition of phosphate leads to complete signal depletion 




constant for the different used phosphate concentrations were obtained after plotting 
the different spectra with a single exponential equation showing a kcat of >400*s
-1 for 
the highest used phosphate concentration of 25 mM. The rate constant for unspecific 
hydrolysis in abscence of phosphate were estimated as described by Gibson et al. 133. 
For hydrolysis the rate constant turned out to be ~0.3 s-1. This means in turn that 
phosphorolysis is more than three orders of magnitude faster than the described signal 
depletion in absence of phosphate. This result indicates that phosphate accelerates the 
tautomerization of the enolAcThDP followed by phosphorolysis. Thus it can be proposed 
that phosphate not just acts as a substrate but that it has an own catalytic function and 
participates to the reaction in a substrate assisted catalysis (SAC) manner (Figure 55). 
 
 
Figure 55: Phosphate catalyzed tautomerization of enolAcThDP to ketoAcThDP. 
 
Substrate assisted catalysis has been described for several enzymes like serine 
proteases, type II restriction endonucleases and the G protein-coupled receptor RAS 86. 
In this regard the substrate usually performs a catalytic function, which one would 
usually expect for an amino acid residue within the active center of the respective 
enzyme. In case of phosphate containing substrates it has been shown that in several 
cases phosphate acts as acid base catalyst in such enzymes like EcoRI, EcoRV, aspartyl-, 




Moreover in the G protein-coupled receptor RAS p21 the terminal phosphate of the 
GTP-substrate stabilizes an occurring intermediate by formation of a hydrogen bond 138. 
All these SAC mechanisms have been described on basis of structural studies of the 
corresponding enzymes, by substrate analog usage, by the stereo-chemistry of the 
reaction or, in case of ras P21, by free-energy relationships. 
 
4.3 1H NMR spectroscopic product analysis 
To further validate our assumption that indeed the enol form of AcThDP is accumulated 
in the active center of XFPK as an intermediate, 1H NMR spectroscopy experiments have 
been performed according to a method described earlier 103. First, ThDP-intermediate 
analysis has been performed to analyze the over-all distribution of detectable ThDP-
intermediates within XFPK driven catalysis. In presence of F6P, the only detectable 
intermediate was AcThDP (Figure 30). This can be explained with AcThDP either being a 
dead-end product, or a true occurring intermediate. In light of our UV/vis stopped-flow 
experiments the latter seems to be more likely, although a distinction between the enol 
and keto form is under the chosen pH conditions not possible. With F6P and phosphate 
present the DhThDP-intermediate was detectable (Figure 30). It is reasonable that the 
AcThDP can be detected only in the absence of phosphate since the tautomerization 
followed by hydrolysis seems to be the rate limiting step and is accelerated by several 
orders of magnitude in presence of phosphate. Moreover it is questionable why the 
expected F6P-ThDP adduct could not be detected, although it should occur under these 
conditions as it was reported for other F6P-converting ThDP-dependent enzymes 38. The 
most likely explanation might be its transient character 80. 1H NMR analysis of the active 
site histidine variants could not be performed to a greater extend so far, but their 
evaluation should clearly show which histidine serves as acid/base catalyst at which 
point of XFPK catalysis by accumulating either the F6P- adduct or DhThDP. 
To confirm if the enzyme bound spectroscopically detected ThDP-inermediate can be 
assigned as the enolAcThDP we performed product analysis 1H NMR spectroscopy H/D 
exchange experiments. In aqueous solution XFPK showed production of acetate while 
incubation with F6P in absence of phosphate (Figure 34). If this intermediate is in a 




incorporated. Performing this experiment in deuterium oxide revealed almost full 
depletion of this signal and only a minor amount of mono- and dideuterated acetate 
(fully deuterated acetate is NMR-silent). This underpins our assumption of the in UV/vis 
experiments detected ThDP-intermediate being enolAcThDP and of phosphate 
accelerating the tautomerization into the ketoAcThDP. 
Our proposed mechanism of phosphate mediated SAC is to our knowledge the first 
description of this phenomenon by a direct spectroscopic method and of anorganic 
phosphate changing the chemical state of a substrate. In the ThDP-dependent enzyme 
class this would be an additional catalytic mechanism and might explain, how the 
enzyme enables the weak nucleophile phosphate to phosphorolyse the enzyme bound 
AcThDP. 
 
4.3.1 Glutamate 437 seems to play a role in phosphorolysis 
The glutamate 437 of XFPK seems to have an important function within XFPK mediated 
catalysis. ITC and acetyl phosphate detection based activity assays showed that the 
exchange of glutamate against glutamine leaded to a variant which is inactive, even with 
an increase of the used enzyme concentration of up to 2 mg/mL (Figure 36). Moreover 
in UV/vis stopped-flow analysis no putatively enolAcThDP-intermediate signal could be 
detected (Figure 37). Near-UV CD pH-titration showed bound cofactor, with the IP signal 
already present under initial conditions (Figure 38). It seems as if the glutamine either 
affects the tautomeric equilibrium of the cofactor, or that the glutamate of the wildtype 
quenches the IP signal at lower pH values. By performing substrate-soaking experiments 
during crystallization of this variant, additional electron density could be detected at the 
C2 of the thiazolium ring of the cofactor. This electron density has been assigned to 
AcThDP (Figure 40). This is contradictory, since in that case the variant is able to catalyze 
all steps from substrate-binding up to the formation of the last enzyme-bound 






Putatively the last step of catalysis (nucleophillic attack of phosphate) is hampered due 
to the high flexibility of the phosphate binding anchor tyrosine 501. Moreover the 
exchange of glutamate 437 to glutamine seems to affect the spectroscopic behavior of 
the intermediate since after the exchanging no enolAcThDP specific signal could be 
detected. As mentioned above a simple enol should show absorption at 280 nm. In case 
of the wild-type the red-shifted absorption at 420 nm is most likely caused by an 
influence of the aminopyrimidine ring of the cofactor. The glutamate seems to play a 
role in this “information” transfer from the aminopyrimidine to the bound intermediate 
resulting in the observed absorptionpatter. 
 
4.4 Transketolase-like protein 1 and 2 
4.4.1 Expression and purification of a chaperone TKTL1 and 2 fusion 
construct 
Attempts to establish a recombinant expression system for TKTL1 and 2 in prokaryotes 
and eukaryotes failed and led to mainly insoluble protein in both cases (Figure 41) 
(Figure 42). This is a common problem while expressing human genes in E.coli since 
certain factors like post-translational modifications or interactions with other human 
derived proteins are not possible 139. To overcome this restriction a stepwise adaption of 
Figure 56: Microscopic steps of XFPK. The E437Q variant seems to be unable to catalyze the last step, 




the expression protocol can be applied consisting of five different approaches. These are 
(1) change of the expression vector, (2) change of the host, changing the culture 
parameters of the host-strain, (4) co-expression of other genes and (5) changing the 
gene sequence in terms of codon-optimization 140. All these attempts have been 
performed as outlined in the results part with the exception of co-expression of other 
genes. In all cases insufficient amounts of soluble TKTL1 and 2 could be obtained. To 
enhance this low amount of soluble enzyme a fed-batch derived expression protocol 
was performed, increasing the total yield of E.coli cell material. By this the yield of TKTL1 
and 2 that could be obtained was in the mg scale. Besides TKTL1 and 2 the E.coli derived 
chaperone DnaK becomes co-purified, which is a common phenomenon of recombinant 
expression in E.coli 119. Removing DnaK leads to precipitation of TKTL1 and 2. It seems 
that by the interaction of the TKTL-proteins with the chaperone the desired proteins 
were held in solution. Basing on this result TKTL1 and 2 were fused to the trigger factor 
chaperone which increased solubility of the proteins and the solubility-problem could be 
overcome (Figure 43). 
 
4.4.2 Biochemical analysis cofactor binding and of enzymatic TKTL1 and 2 
activity 
Biochemical and biophysical analysis of TKTL1 and 2 was performed with established 
protocols of native human TKT 50. TKTL1 and 2 showed no enzymatic activity with X5P as 
substrate in an enzyme-linked spectroscopically assay as previously reported 53. 
Moreover, CoA was provided as second substrate for putative TKTL1 or 2 reactions. 
Neither, in an enzyme-linked spectroscopic assay, nor when performing a product 
analysis be means of mass spectrometry the expected products G3P or acetyl-CoA could 
be detected (Figure 45-48). This is in striking contrast to previously published results 53. 
To rule out if this lack of enzymatic activity is caused by improper protein folding far-UV 
CD analysis has been performed with the fusion constructs of the TKTL1/2-trigger factor 
constructs as well as the TKTL1 and 2 obtained after protease cleavage of the trigger 
factor. All constructs seem to generate a secondary structure which is characteristic for 
correctly folded proteins, although thermal stability was slightly decreased in 




ThDP as cofactor near-UV CD experiments have been performed as outlined for TKT and 
TKT∆38. None of the constructs showed a characteristic negative AP signal centered at 
320 nm. This suggests that TKTL1 and 2 either cannot bind ThDP or that the cofactor is in 
a spectroscopically silent state (Figure 49). So far 1H NMR spectroscopy experiments and 
crystallization could not be performed to confirm the absence of ThDP within TKTL1. 
Based on these results it seems unlikely for TKTL1 to feed-forward a malignent cells’ 
glycolytic metabolism by an intrinsic catalytic function. On the other hand it is 
astonishing that TKTL2 shows no ThDP-derived enzymatic activity since it has a higher 
homology to native TKT. The deletion of 38 amino acids which mainly differs TKTL1 from 
TKT is not present in TKTL2 and despite two additional amino acid changes (see 
appendix) all invariant TKT-specific residues are conserved 35. 
Slow consumption of X5P by TKTL1 as published earlier was measured over a period of 
more than 24 h 53. While incubating the trigger factor fused TKTL1 and 2 constructs 
under the same conditions as reported without adding substrate, a very slow oxidation 
of NADH can be detected (see appendix). This is most likely caused by co-purified 
protein impurities. These impurities can be removed after protease-mediated release of 
TKTL1 and 2 (followed by SEC) and the unspecific oxidation of NADH vanishes (Figure 
45). The published enzymatic data of TKTL1 were performed with samples showing a 
comparable impure band pattern in SDS-PAGE analysis 53. The authors assume these 
impurities to be unspecific C-terminal cleavage products but they do not underpin this 
assumption by mass spectrometric analysis or western-blotting against the fused 
hexahistidine sequence. Within the published coupled NADH-consumption assays no 
control has been shown where TKTL1 was incubated without X5P. Therefore it seems 
likely that the reflected slow NADH consumption after substrate addition over 24 h is an 
unspecific side effect based on impure TKTL1 samples as detected for our trigger-factor 
TKTL1 constructs. This outcome once more emphasizes the inconsistencies in the field of 
TKTL1 research. 
The only evidences of an intrinsic TKTL1-activty are the previously discussed NADH 
consumption assay, and another study in which TKTL1 was described as capable of 
restoring the function of TKT in the PPP. In the mentioned study chronic myeloid 




blast-crisis 141. This transition is characterized by developing a resistance against 
Imatinib, an inhibitor of the BCR-ABL kinase, whose activity is indispensable for this type 
of cancer. It was shown that the non-oxidative part of the PPP seems to play an 
important role in this resistance mechanism and that knock-down of TKT can restore 
sensitivity towards Imatinib. TKT knocked-down cells which were additionally 
transfected with a TKTL1 construct regained their resistance towards Imatinib. In light of 
a likely missing intrinsic catalytic function of TKTL1 this result is hard to explain. 
 
4.4.3 The role of TKTL1 in tumorigenesis needs to be further evaluated 
If TKTL1 plays a role in tumorigenesis it will, due to the above mentioned reasons, rather 
be caused by an enzymatic activity and more likely based on an interaction with other 
proteins. In this regard HIF1α, one of the two subunits of the transcription factor HIF, 
has come into focus 70. Overexpression of TKTL1 was shown to stabilize the oxygen-
sensitive HIF1α subunit under normoxic conditions, leading to induction of several 
downstream target genes of the HIF1 transcription factor cascade. Dysregulation of 
HIF1α has previously been reported as potential cause for an increased “aerobic 
glycolysis” in breast cancer cell lines 142. However, this stabilizing effect of TKTL1 on 
Hif1α is disputable in light of the described unspecificity of the TKTL1 antibody 
JFC12T10 75. Most of the so far published studies on TKTL1 expression on the protein 
level used this antibody for TKTL1 detection. Especially immunohistochemical staining by 
using this antibody against surgically removed specimens have been performed showing 
a correlation of TKTL1 expression and cancer progression 143 144 145. As discussed by 
Mayer et al. there are alternative TKTL1 antibodies available but so far no studies have 
been published using these antibodies. By comparing immunohistochemical validation 
studies with one of these alternative antibody (HPA000505) (proteinatlas.org) Mayer et 
al. could show that the derived data are in contradiction to the so far published TKTL1 
results 122 121. Previously published results on colon, urothelial and renal cell carcinoma 
could not be confirmed with the alternative antibody 121 146. 
Based on this the role in tumorigenesis of TKTL1 can neither be confirmed nor 












Transketolase (TKT) is a ubiquitous distributed enzyme in all three domains of life. Its 
catalytic function is fulfilled within the pentose phosphate pathway (PPP) and the Calvin-
Benson-Bassham cycle of photosynthetic plants. TKTs catalyze the transfer of 1,2-
dihydroxyethyl-fragments from donor ketoses to acceptor aldose in a reversible manner. 
TKT requires bivalent cations and thiamine diphosphate (ThDP) as cofactors. ThDP 
belongs to the best characterized cofactors and enables enzymes to perform a whole 
variety of reactions like formation and breaking of carbon-carbon bonds. Beside its 
central role in carbon metabolism, TKT has been described as potential factor in human 
disease development. Diabetes, Alzheimers’ Disease, the neurological disorder 
Wernicke-Korsakoff syndrome as well as cancer have been described as affected in 
terms of a TKT mediated disease development. Especially the role of TKT in cancer 
seems to be a promising approach to overcome resistance mechanisms of tumor cells. In 
the recent years the concept of an abnormal metabolism in malignant cells has been 
elucidated in more detail since this abnormality could provide an alternative target side 
for cancer drugs. In this context malignant cells have to adjust their metabolic program 
in terms of glucose processing. Glucose can either be used to provide energy in form of 
adenosine triphosphate (ATP) via glycolysis or for generation of reductive equivalents 
and nucleotide precursors in form of nicotineamid adenine dinucleotide phosphate 
(NADPH) and ribose 5-phosphate (R5P) within the PPP. Especially malignant cells have a 
high consumption of R5P and NADPH since these molecules are indispensable for 
anabolic reactions and DNA-synthesis, the two prerequisites for cell division. By 
inhibiting respiration and thereby providing more glucose for the PPP tumor cells seem 
to adjust this balance towards a glycolytic phenotype, ignoring ample oxygen 
concentrations for respiration. 
As mentioned above TKT plays the central role in the PPP and its connection to the 
aforementioned metabolic reprogramming of malignant cells seems reasonable. Besides 
two isoforms of TKT have been discovered sharing a high homology to TKT. One of them, 
the transketolase-like protein 1 (TKTL1) was described to play an important role in 
tumorigenesis. It was shown for several cancer entities that an overexpression of TKTL1 




the corresponding cancer. This was expressed by a higher histopathological staging of 
the corresponding cancers and a lowered over time survival of patients suffering from 
cancer. 
TKTL1 has been described to act on xylulose 5-phosphate (X5P) one of the used 
substrates of native TKT. TKTL1 is supposed to cleave X5P into glyceraldehyde 3-
phosphate (G3P) and a C2 fragment of unknown identity. This C2 fragment was 
supposed to be acetyl Coenzyme A, which would be further processed (i.e. lipid 
synthesis). 
Since biochemical data of TKTL1 a rather scarce and inconclusive, we attempted to 
elucidate the proposed function of TKTL1 in more detail. For that purpose a minimal 
construct of TKTL1 was generated to gain insights into the biochemical features of 
TKTL1. This construct was generated by deleting 38 amino acids out of TKT, since this 
deletion displays the main difference of TKT and TKTL1. Biochemical characterization by 
established protocols for TKT analysis revealed that this deletion leads to catalytical 
inactive protein. This inactivity can be explained by an absent binding of the ThDP 
cofactor. The deleted amino acid sequence contains nine residues which are conserved 
among all known TKTs. Two of them (histidine 77 and 110) are important for cofactor 
binding and catalysis, which explains the loss of catalytic function. Moreover the deleted 
motif seems to affect assembly of the catalytic dimer, a prerequisite for TKT mediated 
catalysis since the dimer represents the smallest catalytic active subunit of this enzyme. 
 
As second approach phosphoketolase (XFPK) of Bifidobacterium breve was characterized 
in terms of its reaction mechanism, since TKTL1 was supposed to show a comparable 
catalytic activity. XFPK performs a partially comparable reaction as TKT. XFPK also uses 
ThDP and bivalent cations as cofactors and acts on the same set of substrates (X5P and 
[fructose 6-phosphate]). However XFPK performs a carbo-lyase reaction whereas TKTs 
shows carbo-ligase activity. The substrate X5P or F6P is cleaved by XFPK which gives rise 
to G3P and acetyl phosphate. During this reaction a nucleophilic attack of inorganic 
phosphate at an enzyme-bound ThDP-substrate intermediate takes place. To compare a 





To our surprise XFPK seems to fulfill a unique catalytic way of action among the ThDP 
enzyme family. It was already proposed that XFPK performs a set of irreversible 
reactions like the dehydration of the enzyme bound dihydroxyethylthiamin diphosphate 
intermediate (DhEThDP), leading to acetyl thiamine diphosphate (AcThDP). The latter is 
subject to phosphorolysis which gives rise to the above mentioned acetyl phosphate. 
In UV/vis stopped-flow experiments we were able to detect an intermediate-species, 
which gave rise to a characteristic absorption at ~420 nm. By comparative analysis of 
active site variants in terms of UV/vis and 1H NMR spectroscopic intermediate analysis 
we propose the detected species to be the enol form of the AcThDP. In this regard the 
addition of phosphate after formation of enolAcThDP led to complete signal depletion 
within a few milliseconds showing that the detected species is a true occurring 
intermediate. Prior to phosphorolysis the enolAcThDP needs to tautomerize into its keto 
form, so phosphate can attack in a nucleophilic manner. By H/D exchange experiments 
we could show that the enzyme bound AcThDP indeed changes dynamically between its 
enol- and keto-form. 
Based on this it seems that phosphate accelerates this tautomerization by more than 
three orders of magnitude, acting in a substrate assited catalytic manner. This unique 
catalytic mechanism has to our knowledge not been described in terms of a direct 
spectroscopic observation with inorganic phosphate as catalyst, changing the chemical 
nature on an enzyme bound intermediate. 
 
To further characterize a putative TKTL1 mediated catalytic function TKTL1 as well as 
TKTL2 were recombinantly expressed and analysed for enzymatic activity and ThDP 
cofactor binding as the previously described deletion variant. Neither in a coupled 
enzymatic assay, nor while performing mass spectrometric product analysis a 
noteworthy catalytic activity was detected. This absence of a ThDP mediated catalytic 
activity seems to be caused by the disability of TKTL1 and 2 to bind the ThDP cofactor, as 
judged by circular dichroism measurements. Therefore a role in tumorigenesis of TKTL1 
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Figure 57: Sequence alignment of hTKT (p29401) against TKTL2 (pQ9H0I9). Numbering corresponds to the sequence 
of human TKT. Secondary structure elements are extracted from pdb-structure 3MOS (hTKT). Identical residues are 
highlighted by a red background, similar ones by red characters. Asterisks mark residues which are invariant amongst 









Table 5: X-ray statistics for B.breve XFPK in ground state with native cofactor ThDP, or refined with 
Dihydrothiachromin. 






Data collection statistics    
Space group “ I422 “ 
Unit cell (Å)  a = 174.7  
  b = 174.7  
  c = 163.6  
Beam line  PIII P13  
Wavelength (Å)  0.8248  
Resolution Range (Å)  50-1.48 (1.604-1.48)  
Number reflections  1227798 (256166)  
Unique reflections  206660 (44003)  
Completeness (%)  99.8 
(99.9) 
 
Rmerge (%)  6.8 (58.3)  
I/σI  17.19 (3.31)  
Redundancy  5.9 (5.8)  
Refinement statistics    
Resolution range (Å) 46.4-1.48 50-1.48 41.14-1.48 
No. of reflections 196316 (10333) 196316 (10333) 196316 (10333) 
R-factor/Rfree (%) 16.02/17.37 16.02/17.37 15.56/17.12 
Number of atoms    
Protein 6381 6420 6420 
Ligands 97 71 71 
Water 812 1026 1027 
B-factor protein 26.23 19.75 19.49 
B-factor ligands 27.52 19.85 21.68 
B-factor Water 37.25 35.29 34.99 
Deviations from ideal 
(r.m.s.d.) 
   
Bond distances (Å) 0.007 0.007 0.007 
Bond angles (°) 1.221 1.223 1.23 
Dihedrals (°) 13.689 14.06 14.13 
Ramachandran plot    
Favoured regions (%) 96.75 96.6 96.75 
Allowed regions (%) 3.25 3.4 3.25 





Table 6: X-ray statistics for B.breve XFPK in complex with 1,2-dihydroxyethyl thiamindiphosphate (DhEThDP) or 2-
acetyl thiamindiphosphate (AcThDP). 
Data set XFPK E437Q 
AcThDP 
XFPK DhThDP 
Data collection statistics   
Space group I422 “ 
Unit cell (Å) a = 174.3  
 b = 174.3  
 c = 163.3  
Beam line PIII P13  
Wavelength (Å) 0.8248  
Resolution Range (Å) 50-1.6 (1.7-
1.6) 
 
Number reflections 592371 
(97584) 
 
Unique reflections 160690 
(26467) 
 
Completeness (%) 98.2 (98)  
Rmerge (%) 8 (86.1)  
I/σI (15.78 (2.22)  
Redundancy 7.37  
Refinement statistics   
Resolution range (Å) 1.6-38.8 1.6-38.8 
No. of reflections 160625 160625 
R-factor/Rfree (%) 16.56(19.31 16.3/19.1 
Number of atoms   
Protein 7533 6391 
Ligands 75 74 
Water 1043 1059 
B-factor protein 16.2 16.41 
B-factor ligands 22.9 23.81 
B-factor Water 30.49 30.89 
Deviations from ideal 
(r.m.s.d.) 
  
Bond distances (Å) 0.018 0.018 
Bond angles (°) 1.787 1.773 
Dihedrals (°) 14.08 14.08 
Ramachandran plot   
Favoured regions (%) 96.5 96.5 
Allowed regions (%) 3.5 3.5 
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Figure 59: SDS PAGE analysis of purified XFPK 
variants.  






Figure 60: Temperature-induced unfolding of selected XFPK variants. Thermal unfolding was performed as described 










































































































































































ITC kinetics calculations 
Chemical reactions are driven by decrease in free energy which is summed up by the 
entropic and enthalpic term: 
 
∆𝐺 = ∆𝐻 − 𝑇∆𝑆       [3] 
 
Therefore by determining the amount of heat that isproduced within an enzyme 
mediated substrate conversion, the reaction rate is accessible. In this case power is 





       [4] 
 
The conversion of n moles of substrates to product is associated with the amount of 
produced heat by 
 
𝑄 = 𝑛 ∗ ∆𝐻𝑎𝑝𝑝 = [𝑃]𝑡𝑜𝑡𝑎𝑙 ∗ 𝑉 ∗ ∆𝐻𝑎𝑝𝑝                                                [5]  
 
V  =  volume of the solution in the reaction cell 
P  = concentration of the generated product 
∆Happ  = experimentally determined molar enthalpie of the reaction 
 
By this the reaction rate of an enzymatically driven reaction can be deduced from the 


























The reaction rate (units of power) needs to be converted into into enzyme turnover to 
get a full kinetic characteization of the reaction. For this the apparent molar enthalpy 
(∆Happ) of the reaction must be known. This can be done by determining the total 















Figure 61: The active center histidine variants of XFPK were analyzed by near-UV CD spectroscopy for ThDP binding 
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BbXFPK H64A (1 mg/mL) in Pipes/Tris/MES (20 mM)
Wavelength (nm)
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BbXFPK H142A (1 mg/mL) in Pipes/Tris (20 mM)
Wavelength (nm)
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BbXFPK H320A (1 mg/mL) in MES/Pipes/Tris (20 mM)
Wavelength (nm)
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BbXFPK H553A (1 mg/mL) in MES/Pipes/Tris (20 mM)
Wavelength (nm)
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BbXFPK E437Q (1 mg/mL) in Pipes/Tris/MES (20 mM)
Wavelength (nm)















buffer     pH 7.97
pH 6.46   pH 8.51
pH 7.04   pH 9.03
pH 7.53   
Wavelength (nm)


















Figure 63: Time resolved PDA spectra of XFPK driven F6P conversion. First phase of F6P conversion by XFPK variants 
in 20 mM Hepes (pH 7.2) containing 1 mM MgCl2 and 100 µM ThDP at 25 °C in a stopped-flow spectrometer with a 
pathlength of 10 mm. Only the H142A variant shows slight intermediate formation. Insert shows reaction of wild type 
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Figure 62: Near-UV spectra 
analysis of XFPK at a 
concentration of 1 mg/mL 
enzyme in Hepes (pH 7.2). 
Addition of 5 mM F6P leads to a 
strong absorption signal below 
320 nm since the released E4P 

















Figure 65: Analysis of intermediate generation after XFPK H64A variant driven conversion 
of F6P by 1H-NMR spectroscopy. Addition of F6P or F6P and phosphate leads to generation 
of multiple signals in the intermediate region. This is caused most likely by cofactor 





Figure 64: Analysis of intermediate generation after XFPK H97A variant driven conversion 
of F6P by 1H-NMR spectroscopy. It seems as if this variant is unable to bind ThDP after 





Figure 66: Simulated annealing 2|Fo|-|Fc| omit map of dihydrothiachromin. As outlined in the results part, in the 
resting state of the E437Q variant missing electron density at the C2 of the thiazolium could be observed. Besides 
additional electron density seems to be located between the mentioned C2 and the N4’ of the aminopyrimidine ring 
of the cofactor. Suzuki et al. reported a comparable phenomenon while determining the structure of the H64A 
variant. They stated the additional electron density to be a tricyclic form of the ThDP cofactor as reported earlier by 
Washabaugh et al. for free ThDP and Pang et al. for ThDP bound to the active center of Klebsiella pneumoniae 
















1 2 3 4 5 6 Figure 67: SDS-PAGE analysis of thrombin and 
HRV 3C digested TFTKTL1 and 2. 1) TFTKTL2 2) 
TFTKTL1 3) thrombin digested TKTL2 4) thrombin 
digested TKTL1 5) HRV 3C TKTL2 6) HRV 3C TKTL1 
Time (sec)















Figure 68: Steady-state kinetic analysis of enzymatic activity of TFTKTL1 and 
2. The TKTL1 (solid line) and 2 (dashed line) fusion constructs showed slow 
consumption of NADH (340 nm) at 30 °C even in the abscence of the putative 









Figure 69: Secondary structure signals as recorded by circular 
dichroism. Solid line α-helix, long dashed line β-sheet, dotted line type I 
β-turn, cross dashed line, extended 31 helix or poly (pro) II helix, short 
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